Initial Dosing for Lantus (Insulin Glargine) in Patients Requiring Insulin Therapy

Dosing Guidelines

• The American College of Physicians recommends an initial dose of 10 units or 0.1-0.2 units/kg of body weight once daily for patients requiring insulin therapy, according to the American Diabetes Association guidelines 1, 2, 3
• For type 2 diabetes patients, the initial dose is typically 10 units or 0.1-0.2 units/kg of body weight once daily, often used with metformin and possibly one additional non-insulin agent, as recommended by the American Association of Clinical Endocrinologists 1, 2, 3
• Consider higher starting doses (basal-bolus regimen) for type 2 diabetes patients with HbA1c ≥ 9%, blood glucose levels ≥ 300-350 mg/dL, or HbA1c 10-12% with symptomatic or catabolic features, as suggested by the American College of Physicians 1, 3

Dose Titration

• Increase the dose by 10-15% or 2-4 units once or twice weekly until fasting blood glucose target is met, as recommended by the American Diabetes Association 4
• Timely dose titration is important for achieving glycemic goals, according to the American Association of Clinical Endocrinologists 1, 3

Common Pitfalls to Avoid

• Delaying insulin therapy in patients not achieving glycemic goals can be harmful, as stated by the American College of Physicians 1, 3
• Not adjusting doses based on self-monitoring of blood glucose levels can lead to poor glycemic control, as recommended by the American Diabetes Association 1, 2

Special Populations

• For patients on enteral/parenteral feeding requiring insulin, basal insulin needs are typically 30-50% of the total daily insulin requirement, as suggested by the American Society for Parenteral and Enteral Nutrition 5
• A reasonable starting point for these patients is 5 units of NPH/detemir insulin every 12 hours or 10 units of insulin glargine every 24 hours, according to the American Diabetes Association 5

Insulin Glargine Dosing Guidelines

Dosing Recommendations

• The American Diabetes Association recommends a starting dose of 0.4 to 1.0 units/kg/day of total insulin for type 1 diabetes patients, with 0.5 units/kg/day being typical for metabolically stable patients 6, 7
• For type 1 diabetes patients, higher weight-based dosing is required immediately following presentation with ketoacidosis 6
• Lantus provides basal insulin coverage, but rapid-acting insulin will be needed at mealtimes to control postprandial glucose 6
• The recommended starting dose for insulin-naive type 2 diabetes patients is 0.1-0.2 units/kg/day 8

Dose Titration and Adjustment

• The American Diabetes Association suggests increasing the dose by 2-4 units every 3-4 days until fasting blood glucose reaches target range (80-130 mg/dL) 8
• If fasting glucose is ≥180 mg/dL, consider increasing the dose by 4 units 8

Common Pitfalls to Avoid

• Overbasalization, using higher than necessary basal insulin doses, can mask insufficient mealtime insulin coverage, with signs including high bedtime-to-morning glucose differential (≥50 mg/dL), hypoglycemia, and high glucose variability 9

Insulin Glargine Dosage Guidelines

Recommended Starting Doses

• For patients on enteral/parenteral feeding requiring insulin, a reasonable starting point is 5 units of NPH/detemir insulin every 12 hours or 10 units of insulin glargine every 24 hours 10
• For type 1 diabetes, total daily insulin requirements typically range from 0.4 to 1.0 units/kg/day, with 0.5 units/kg/day being typical for metabolically stable patients 11

Patient Transition and Titration

• For patients transitioning from oral medications to insulin therapy, 5 units of Lantus nightly may be appropriate 12
• Most patients can be taught to uptitrate their own insulin dose, typically adding 1-2 units (or 5-10% for higher doses) once or twice weekly if fasting glucose levels remain above target 12

Changing Insulin Requirements

• Failure to recognize that insulin requirements may change with weight changes, illness, or changes in physical activity 12

Initial Insulin Dosing for Diabetes Management

Basal Insulin Initiation

• For a 50kg patient with diabetes, the American Diabetes Association recommends starting with 10 units of basal insulin once daily, administered at the same time each day 13
• For patients on enteral/parenteral feeding requiring insulin, the American Diabetes Association suggests a reasonable starting point is 10 units of insulin glargine every 24 hours 14

Insulin Regimen Selection

• For type 2 diabetes patients with mild hyperglycemia, the European Association for the Study of Diabetes recommends a basal-only approach may be sufficient initially 15
• For type 1 diabetes patients, the American Diabetes Association requires a basal-bolus regimen, with approximately 50% of the total daily insulin dose as basal insulin and 50% as prandial insulin 16
• Total daily insulin requirements typically range from 0.4 to 1.0 units/kg/day for type 1 diabetes patients, according to the American Diabetes Association 16

Dose Titration

• The American Diabetes Association recommends increasing the basal insulin dose by 2 units every 3 days until fasting blood glucose target is reached 17
• If hypoglycemia occurs, the American Diabetes Association suggests determining the cause and reducing the dose by 10-20% 13

Adding Prandial Insulin (If Needed)

• The American Diabetes Association recommends adding prandial insulin if basal insulin alone is insufficient to reach glycemic targets 13
• For prandial insulin initiation, the American Diabetes Association suggests starting with 4 units per day or 10% of the basal dose with the largest meal 13

Special Considerations

• The European Association for the Study of Diabetes notes that lower weight patients may be more sensitive to insulin and at higher risk for hypoglycemia 15
• For patients with higher risk of hypoglycemia, the European Association for the Study of Diabetes recommends using the lower end of the dosing range 15

Lantus Titration Protocol for Optimal Glycemic Control

Initial Dosing and Titration

• The American Diabetes Association recommends starting with 10 units per day or 0.1-0.2 units/kg body weight once daily, administered at the same time each day 18
• For patients with more severe hyperglycemia, consider higher initial doses (0.3-0.4 units/kg/day) 19

Titration Algorithm

• Set a fasting plasma glucose goal based on individualized glycemic targets and increase dose by 2 units every 3 days until reaching the target without hypoglycemia 18
• If A1C remains above goal after 3-6 months of basal insulin titration despite reaching FPG targets, consider adding prandial insulin 18, 19

Monitoring and Adjustments

• Monitor fasting blood glucose daily during titration and assess adequacy of insulin dose at every visit, looking for clinical signals of overbasalization 18, 19
• Daily self-monitoring of blood glucose is essential during the titration phase 19

Important Considerations

• Be aware that once daily basal insulin dose exceeds 0.5 units/kg/day, addition of prandial insulin may be more appropriate than further basal insulin increases 18, 19

Insulin Dose Adjustment for Suboptimal Glycemic Control

Target Blood Glucose Levels

• The American Diabetes Association recommends a fasting glucose target of 80-130 mg/dL (4.4-7.2 mmol/L) 20

Basal Insulin Dose Adjustment

• When basal insulin exceeds 0.5 units/kg/day and approaches 1.0 units/kg/day, consider adding mealtime insulin rather than continuing to escalate basal insulin alone, as recommended by the American Diabetes Association 21

Initial Therapy

• The foundation of type 2 diabetes therapy should include metformin unless contraindicated, as recommended by the American Diabetes Association 22, 23

Prandial Insulin Therapy

• Consider adding prandial insulin if after 3-6 months of basal insulin optimization, fasting glucose reaches target but HbA1c remains above goal, or if significant postprandial glucose excursions occur, as recommended by the American Diabetes Association 21
• Add prandial insulin before the meal causing the greatest glucose excursion, as recommended by the American Diabetes Association 21

Monitoring and Avoiding Pitfalls

• Daily self-monitoring of fasting blood glucose is essential during titration, as recommended by the American Diabetes Association 21
• Ignoring the need for prandial insulin and continuing to escalate basal insulin beyond 0.5-1.0 units/kg/day without addressing postprandial hyperglycemia leads to suboptimal control and increased hypoglycemia risk, as warned by the American Diabetes Association 21

Insulin Dose Titration for Hyperglycemia Management

Introduction to Insulin Titration

• The American Diabetes Association recommends basal insulin doses of 0.4-0.6 units/kg for patients with severe uncontrolled hyperglycemia, with systematic uptitration every 3 days until fasting glucose reaches 80-130 mg/dL 24

Basal Insulin Titration

• For patients with fasting glucose ≥180 mg/dL, the evidence-based titration algorithm specifies an increase in basal insulin by 4 units every 3 days until target glucose levels are reached 24
• If fasting glucose is 140-179 mg/dL, basal insulin should be increased by 2 units every 3 days 24

Prandial Insulin Coverage

• When basal insulin approaches 0.5-1.0 units/kg/day and fasting glucose is controlled but A1C remains elevated, adding prandial insulin becomes necessary rather than continuing to escalate basal insulin 25, 26
• Prandial insulin coverage should start with 4 units of rapid-acting insulin before the largest meal (or 10% of basal dose), with additions to other meals based on glucose patterns 24, 25, 26

Alternative Therapies

• Consider adding a GLP-1 receptor agonist to the basal insulin regimen to improve A1C while minimizing weight gain and hypoglycemia risk 24, 26

Monitoring and Adjustments

• Daily fasting blood glucose monitoring is recommended during the titration phase, with reassessments every 3 days during active titration and every 3-6 months once stable 24
• If hypoglycemia occurs, determine the cause and reduce the dose by 10-20% 24

Initiating Dose of Lantus for Type 2 Diabetes

Type 2 Diabetes Starting Dose

• The American Diabetes Association guidelines support a starting range of 0.1-0.2 units/kg/day for insulin-naive type 2 diabetes patients, with a typical dose of 10 units once daily for a 50 kg patient 27
• Increase by 2-4 units every 3-4 days until fasting blood glucose reaches target range (80-130 mg/dL), as recommended by the American Diabetes Association 27

Special Considerations and Common Pitfalls

Critical Pitfall: Overbasalization

• Be vigilant for overbasalization when basal insulin exceeds 0.5 units/kg/day, with clinical signals including basal dose >0.5 units/kg/day, high bedtime-to-morning glucose differential (≥50 mg/dL), hypoglycemia, and high glucose variability 27
• When basal insulin approaches 0.5-1.0 units/kg/day and A1C remains elevated despite controlled fasting glucose, add prandial insulin rather than continuing to escalate basal insulin, as recommended by the American Diabetes Association 27

Insulin Glargine Dosing Guidelines

Initial Dosing and Titration

• For hospitalized patients who are insulin-naive or on low-dose insulin, the American Diabetes Association recommends a total daily dose of 0.3-0.5 units/kg, with half as basal insulin, according to The Lancet Diabetes and Endocrinology 28
• For patients on high-dose home insulin (≥0.6 units/kg/day), The Lancet Diabetes and Endocrinology suggests reducing the total daily dose by 20% to prevent hypoglycemia 28
• Lower doses (0.1-0.25 units/kg/day) are recommended for high-risk patients, such as the elderly (>65 years), those with renal failure, or poor oral intake, as stated in The Lancet Diabetes and Endocrinology 28
• The American Association of Clinical Endocrinologists may recommend alternative titration approaches, such as increasing the dose by 10-15% or 2-4 units once or twice weekly, until the fasting blood glucose target is met, according to The Lancet Diabetes and Endocrinology 28

Special Populations and Situations

• For patients without diabetes on steroids, the Endocrine Society suggests a single morning dose of NPH may be appropriate, while for patients with diabetes on steroids, adding 0.1-0.3 units/kg/day glargine to the usual insulin regimen is recommended, with doses determined by steroid dose and oral intake, as stated in The Lancet Diabetes and Endocrinology 29

Administration Guidelines

• The American Diabetes Association advises against diluting or mixing Lantus with any other insulin or solution due to its low pH, as reported in Diabetes Care 30

Management of Inadequate Glycemic Control on Basal Insulin Monotherapy

Immediate Dose Adjustment Algorithm

• The American Diabetes Association recommends increasing the basal insulin dose by 10-15% (approximately 4-6 units) and adding prandial insulin coverage before the largest meal, as blood glucose levels in the 200s mg/dL indicate both inadequate basal insulin and likely insufficient mealtime coverage 31
• Basal insulin titration should be based on fasting glucose levels, with an increase of 4 units every 3 days if fasting glucose ≥180 mg/dL, or by 2 units every 3 days if fasting glucose is 140-179 mg/dL, until fasting blood glucose reaches 80-130 mg/dL 31
• When basal insulin exceeds 0.5 units/kg/day and glucose remains elevated, adding prandial insulin is more appropriate than continuing to escalate basal insulin alone, as recommended by the American Association of Clinical Endocrinologists 31

Adding Prandial Insulin Coverage

• The American Diabetes Association suggests starting with 4 units of rapid-acting insulin before the largest meal or the meal causing greatest postprandial glucose excursion, or alternatively, using 10% of the current basal dose (approximately 4 units) 31, 32
• Rapid-acting insulin analogs provide better postprandial glucose control than regular insulin, according to the Endocrine Society 32, 33
• Prandial insulin should be titrated by 1-2 units or 10-15% every 3 days based on pre-meal and 2-hour postprandial glucose readings, as recommended by the American Diabetes Association 31

Ensure Optimal Foundation Therapy

• The American Diabetes Association recommends verifying that the patient is on metformin unless contraindicated, as it remains the foundation of type 2 diabetes therapy, and metformin should be continued when adding or intensifying insulin therapy 31, 34, 35, 32

Common Pitfalls to Avoid

• Continuing to increase basal insulin beyond 0.5-1.0 units/kg/day without addressing postprandial hyperglycemia leads to suboptimal control and increased hypoglycemia risk, as warned by the American Association of Clinical Endocrinologists 31
• Blood glucose in the 200s mg/dL likely reflects both inadequate basal coverage AND postprandial excursions requiring mealtime insulin, according to the American Diabetes Association 31, 32
• Scheduled insulin regimens with basal, prandial, and correction components are preferred over relying solely on correction insulin, as recommended by the Endocrine Society 36, 37

Patient Education Requirements

• Proper insulin injection technique and site rotation should be taught to patients, as recommended by the American Association of Diabetes Educators 32, 33
• Recognition and treatment of hypoglycemia, self-monitoring of blood glucose, "sick day" management rules, and insulin storage and handling should be included in patient education, according to the American Diabetes Association 31, 32, 33

Initiating Long-Acting Insulin Therapy

Indications for Basal Insulin

• The American Diabetes Association recommends starting long-acting basal insulin when oral medications and/or GLP-1 receptor agonists fail to achieve glycemic targets (A1C >7% for most adults, <6.5% for youth with type 2 diabetes), or immediately in patients with severe hyperglycemia (A1C ≥9%, blood glucose ≥300-350 mg/dL, or symptomatic/catabolic features) 38, 39
• For adults with type 2 diabetes, the American Diabetes Association suggests starting basal insulin when A1C >7% despite optimal oral medications (metformin plus additional agents) 38
• The American Diabetes Association recommends considering starting insulin earlier in the treatment algorithm for adults with type 2 diabetes and A1C ≥9% 38, 40
• For adults with type 2 diabetes and blood glucose ≥300-350 mg/dL and/or A1C 10-12% with symptomatic or catabolic features, the American Diabetes Association recommends starting basal-bolus insulin immediately 38, 40
• The American Diabetes Association suggests starting basal insulin in youth with type 2 diabetes and A1C >8.5% without acidosis or ketosis, at a dose of 0.5 units/kg/day, in addition to metformin 41, 39

Initial Dosing and Titration

• The American Diabetes Association recommends a starting dose of 10 units once daily or 0.1-0.2 units/kg/day for insulin-naive patients with type 2 diabetes, administered at the same time each day 38
• For patients with severe hyperglycemia, the American Diabetes Association suggests considering higher starting doses of 0.3-0.4 units/kg/day 38
• The American Diabetes Association recommends titrating the dose by 2-4 units (or 10-15%) once or twice weekly until fasting blood glucose reaches 80-130 mg/dL 38

Special Considerations

• The American Diabetes Association recommends not delaying insulin initiation in patients not achieving glycemic goals with oral medications 40
• The American Diabetes Association suggests adding prandial insulin when basal insulin has been optimized (fasting glucose 80-130 mg/dL) but A1C remains above target after 3-6 months, or when basal insulin dose approaches 0.5-1.0 units/kg/day without achieving A1C goal 38

Insulin Glargine Dose Titration for Persistent Hyperglycemia

Adjusting Basal Insulin Dose

• If more than 2 fasting glucose values per week are less than 80 mg/dL, decrease the basal insulin dose by 2 units, as recommended by the American Diabetes Association, to prevent hypoglycemia 42

Foundation Therapy

• The American College of Clinical Endocrinologists recommends metformin as the foundation of type 2 diabetes therapy, unless contraindicated, even when intensifying insulin therapy, although the specific details of this recommendation are not provided in the given text, the general principle is supported by various clinical guidelines 42

Ajuste de Insulina Glargina en Diabetes Tipo 1 Descompensada

Consideraciones de Dosis Total

• En diabetes tipo 1, la insulina basal (glargina) típicamente representa 40-60% de la dosis diaria total de insulina, según la American Diabetes Association 43, 44

Protocolo de Titulación de Glargina

• La dosis de glargina puede requerir dosificación dos veces al día cuando la administración una vez al día no proporciona cobertura de 24 horas, según la American Diabetes Association 43, 44

Initiation of Lantus in Specific Clinical Scenarios

Immediate Initiation Criteria

• The European Association for the Study of Diabetes recommends starting basal-bolus insulin immediately in patients with HbA1c 10-12% with symptomatic or catabolic features, suspected type 1 diabetes, or underweight patients, as well as those with acute glycemic dysregulation during hospitalization, surgery, or acute illness 45
• The American Diabetes Association suggests considering immediate initiation of insulin therapy in patients with severe hyperglycemia, although the exact HbA1c threshold is not specified, and GLP-1 receptor agonists may be considered before insulin initiation in patients with no contraindications 45

Insulin Administration and Titration

• The International Diabetes Federation notes that insulin glargine should not be mixed with other forms of insulin due to its low pH diluent, requiring separate injections when combining basal and prandial insulin 46

Basal Insulin Adjustment Timing in Patients on SSI TID

Standard Titration Interval

• The American Diabetes Association recommends increasing basal insulin by 2 units every 3 days to reach fasting plasma glucose goals without hypoglycemia 47
• Basal insulin can be adjusted every 3 days after a change is made, even when patients are concurrently receiving short-acting insulin (SSI) three times daily 47

Key Principle: Separate Basal from Correctional Insulin

• The American Diabetes Association suggests that basal insulin addresses fasting and between-meal glucose levels and should be titrated based on fasting plasma glucose values 47
• Correctional (sliding scale) insulin addresses acute hyperglycemic excursions and does not accumulate to steady state, according to the American Diabetes Association 48
• The two components can be adjusted independently on their respective schedules, as recommended by the American Diabetes Association 47, 48

Monitoring Requirements During Titration

• Assess adequacy of insulin dose at every clinical visit, looking for signs of overbasalization, and adjust the basal dose by 10-20% immediately if hypoglycemia occurs, as recommended by the American Diabetes Association 47

Critical Pitfall to Avoid

• Do not wait longer than 3 days between basal insulin adjustments in stable patients, as this unnecessarily prolongs the time to achieve glycemic targets, according to the American Diabetes Association 47
• The danger of both under-adjusting and failing to respond to hypoglycemia is demonstrated by the 75% of hospitalized patients who experienced hypoglycemia but had no basal insulin dose adjustment before the next administration 48

Special Consideration for Ultra-Long-Acting Insulins

• For ultra-long-acting basal insulins, some experts recommend waiting at least 1 week before making subsequent dose adjustments to fully assess glucose outcomes 49, 50

Timing of Insulin Glargine Adjustment for Post-Lunch Hyperglycemia

Introduction to Basal Insulin Adjustment

• The American Diabetes Association recommends that basal insulin glargine is designed to control fasting and between-meal glucose levels, not postprandial hyperglycemia, with the principal action of basal insulin being to restrain hepatic glucose production overnight and between meals 51, 52, 53

Critical Concepts in Insulin Therapy

• The American Association of Clinical Endocrinologists suggests that continuing to increase basal insulin to address post-lunch hyperglycemia leads to "overbasalization", a dangerous pattern where excessive basal insulin masks the need for mealtime coverage, with clinical signals including bedtime-to-morning glucose differential ≥50 mg/dL, basal insulin dose >0.5 units/kg/day, hypoglycemia, and high glucose variability 51, 52, 54
• Clinical signs of overbasalization include a bedtime-to-morning glucose differential ≥50 mg/dL, indicating excessive basal insulin 51, 52, 54
• A basal insulin dose >0.5 units/kg/day may be a sign of overbasalization, requiring adjustment of the insulin regimen 51, 53

The Role of Prandial Insulin

• The Endocrine Society recommends that when basal insulin has been titrated to achieve acceptable fasting glucose but postprandial hyperglycemia persists, advancement to prandial insulin is necessary, starting with 4 units of rapid-acting insulin before lunch or 10% of the current basal insulin dose 51, 52, 54
• The American Diabetes Association suggests that prandial insulin should be titrated by 1-2 units or 10-15% every 3 days based on post-lunch glucose readings, although the exact titration schedule may vary depending on individual patient needs 51, 52, 54

Alternative Therapies

• The European Association for the Study of Diabetes recommends considering adding a GLP-1 receptor agonist to address postprandial hyperglycemia while minimizing hypoglycemia and weight gain risks, as an alternative to prandial insulin 51, 52, 54

Common Pitfalls to Avoid

• The American Association of Clinical Endocrinologists advises against continuing to escalate basal insulin beyond 0.5-1.0 units/kg/day without addressing postprandial hyperglycemia, as this leads to suboptimal control and increased hypoglycemia risk 51
• The Endocrine Society recommends not delaying the addition of prandial insulin when signs of overbasalization are present, to prevent further complications 51, 52, 54

Insulin Dosing Guidelines for Type 1 and Type 2 Diabetes

Introduction to Insulin Therapy

• The American Diabetes Association recommends starting with a total daily insulin dose of 0.5 units/kg/day for patients with type 1 diabetes on a basal-bolus regimen, giving approximately 50% as Lantus (basal) once daily and 50% as Humalog (prandial) divided among meals 55

Type 1 Diabetes Dosing Algorithm

• For metabolically stable patients with type 1 diabetes, the initial total daily insulin dose is 0.5 units/kg/day, with 40-50% given as Lantus (basal) once daily and 50-60% given as Humalog (prandial) divided among meals 55
• Patients with type 1 diabetes in the honeymoon phase or with residual beta-cell function may require lower doses of 0.2-0.6 units/kg/day 55

Practical Considerations for Insulin Administration

• Humalog must be given immediately before meals (0-15 minutes), not after eating, to effectively manage postprandial glucose levels 55

Special Populations

• Pediatric patients with type 1 diabetes have highly variable total daily insulin requirements, and higher doses are often needed during puberty 55
• Young children and those in the honeymoon phase may require doses as low as 0.2-0.6 units/kg/day 55

Insulin Glargine Dosing Considerations

Dose Adjustment Guidelines

• The American Diabetes Association recommends reducing the dose of Lantus by 10-20% if any episode of severe hypoglycemia occurs, as reported in The Lancet Diabetes and Endocrinology 56

Special Clinical Situations

• In patients with acute illness and poor oral intake, consider lower doses (0.1-0.25 units/kg/day) for high-risk patients, such as the elderly (>65 years) or those with renal failure, although no specific citation is provided in this context, a related guideline from The Lancet Diabetes and Endocrinology suggests careful dose adjustment 56

Insulin Dosing Guidelines

Standard Dosing Ranges by Diabetes Type

• The American Diabetes Association recommends total daily insulin requirements typically ranging from 0.4 to 1.0 units/kg/day for type 1 diabetes, with approximately 50% as basal insulin and 50% as prandial insulin 57, 58
• For metabolically stable type 1 diabetes patients, a typical starting dose is 0.5 units/kg/day 57, 58, 59
• Higher doses are required during puberty, pregnancy, and medical illness for type 1 diabetes, potentially exceeding 1.0 units/kg/day 57, 59
• The American Diabetes Association suggests initial doses for insulin-naive type 2 diabetes patients ranging from 0.1-0.2 units/kg/day for basal insulin 57, 60
• For type 2 diabetes patients with severe hyperglycemia, consider starting with 0.3-0.5 units/kg/day as total daily dose 57, 60
• Total daily doses may exceed 1 unit/kg/day in youth with type 2 diabetes when glycemic targets are not met 61

Special Populations Requiring Higher Doses

• For hospitalized patients on high-dose home insulin (≥0.6 units/kg/day), reduce the total daily dose by 20% upon hospitalization to prevent hypoglycemia 60

Critical Thresholds and Warning Signs

• When basal insulin exceeds 0.5 units/kg/day and approaches 1.0 units/kg/day, consider adding prandial insulin rather than continuing to escalate basal insulin alone 57, 58

Practical Dosing Algorithms

• Calculate 0.5 units/kg/day as total daily dose for type 1 diabetes, dividing 50% as basal insulin and 50% as prandial insulin 57, 58

Common Pitfalls to Avoid

• The Lancet Diabetes and Endocrinology recommends avoiding the use of premixed insulin in hospital settings due to unacceptably high rates of iatrogenic hypoglycemia 60
• Always reduce home insulin doses by 20% when admitting patients on high-dose insulin (≥0.6 units/kg/day) to prevent hypoglycemia 60

Adjusting Basal Insulin for Optimal Glucose Control

Initial Dosing Strategy

• The American Diabetes Association recommends starting basal insulin at 10 units once daily (or 0.1-0.2 units/kg/day) for insulin-naive patients with type 2 diabetes, administered at the same time each day 62
• For patients with more severe hyperglycemia, the American Diabetes Association suggests considering higher starting doses of 0.3-0.4 units/kg/day 62

Evidence-Based Titration Algorithm

• The American Diabetes Association recommends increasing basal insulin by 2 units every 3 days if fasting glucose is 140-179 mg/dL, and by 4 units every 3 days if fasting glucose is ≥180 mg/dL, until fasting plasma glucose reaches target of 80-130 mg/dL 62
• If hypoglycemia occurs without clear cause, the American Diabetes Association recommends reducing the dose by 10-20% immediately 62

Critical Threshold: Recognizing Overbasalization

• The American Diabetes Association suggests stopping escalating basal insulin when the dose exceeds 0.5 units/kg/day and considering adding adjunctive therapy instead 62
• Clinical signals of overbasalization include hypoglycemia, and the American Diabetes Association recommends adding prandial insulin or a GLP-1 receptor agonist rather than continuing to increase basal insulin 62

Advancing Beyond Basal-Only Therapy

• The American Diabetes Association recommends starting with 4 units of rapid-acting insulin before the largest meal or 10% of current basal dose, and increasing prandial insulin by 1-2 units or 10-15% every 3 days based on postprandial glucose readings 62
• The American Diabetes Association suggests considering adding a GLP-1 receptor agonist in combination with basal insulin if not already on a GLP-1 RA or dual GIP/GLP-1 RA 62, 63

Monitoring Requirements

• The American Diabetes Association recommends daily fasting blood glucose monitoring is essential during titration, and assessing adequacy of insulin dose at every clinical visit 62
• The American Diabetes Association suggests looking for clinical signals of overbasalization at each assessment 62

Common Pitfalls to Avoid

• The American Diabetes Association recommends continuing metformin when adding or intensifying insulin therapy unless contraindicated 62

Initial Dosing of Lantus (Insulin Glargine)

Type 2 Diabetes: Standard Initiation

• The American Diabetes Association recommends starting Lantus at 10 units once daily or 0.1-0.2 units/kg body weight once daily for insulin-naive patients with type 2 diabetes, administered at the same time each day 64, 65, 66
• For patients with moderate hyperglycemia, the initial dose can be 10 units once daily, while those with more severe hyperglycemia may require 0.1-0.2 units/kg/day, with the higher end of this range used for more severe elevations 64, 65, 66
• The American Diabetes Association suggests continuing metformin, unless contraindicated, and possibly one additional non-insulin agent when initiating basal insulin 64, 65, 66

Severe Hyperglycemia Requires Higher Starting Doses

• For patients with severe hyperglycemia, characterized by blood glucose ≥300-350 mg/dL and/or A1C ≥10-12% with symptomatic or catabolic features, the American Diabetes Association recommends starting with basal-bolus insulin immediately rather than basal insulin alone 64, 65, 66
• In patients with marked hyperglycemia, but not requiring immediate basal-bolus insulin, a more aggressive approach with starting doses of 0.3-0.4 units/kg/day may be considered to achieve glycemic targets faster in patients with A1C ≥9% 64, 65, 66

Dose Titration Algorithm

• The American Diabetes Association recommends increasing the dose by 2-4 units every 3 days until fasting blood glucose reaches 80-130 mg/dL 64, 65, 66
• Equip patients with self-titration algorithms based on self-monitoring of blood glucose to improve glycemic control 64, 65, 66

Critical Threshold: Recognizing When to Stop Escalating Basal Insulin

• When basal insulin exceeds 0.5 units/kg/day and approaches 1.0 units/kg/day, the American Diabetes Association suggests adding prandial insulin rather than continuing to escalate basal insulin alone 64, 65

Adjusting Lantus Dosage

Titration Schedule

• If more than two fasting blood glucose values per week are less than 80 mg/dL, the dose should be decreased by 2 units, according to the American Diabetes Association, as reported in Diabetes Care 67
• When simplifying complex insulin regimens in older adults, doses should be adjusted every 2 weeks based on finger-stick glucose testing, as recommended by the American Diabetes Association, with a moderate strength of evidence 67

Dose Escalation

• Once basal insulin exceeds 0.5 units/kg/day and approaches 1.0 units/kg/day, consider adding prandial insulin rather than continuing to escalate basal insulin alone, as suggested by the American Diabetes Association, with a high strength of evidence 68
• At this threshold, further increases in Lantus every 3 days may lead to overbasalization rather than improved glycemic control, according to the American Diabetes Association, with a moderate strength of evidence 68

Monitoring Requirements

• Reassess adequacy of insulin dose at every clinical visit, looking specifically for signs of overbasalization, such as bedtime-to-morning glucose differential ≥50 mg/dL, hypoglycemia, and high glucose variability, as recommended by the American Diabetes Association, with a low strength of evidence 68

Insulin Dosing Guidelines

Initial Insulin Dosing

• The American Diabetes Association recommends starting with 10 units once daily or 0.1-0.2 units/kg body weight per day for insulin-naive patients, administered at the same time each day 69
• For severe hyperglycemia, consider higher starting doses of 0.3-0.5 units/kg/day as total daily dose, split between basal and prandial insulin 69
• Continue metformin unless contraindicated when initiating insulin therapy 69

Titration Algorithms

• Increase basal insulin by 2 units every 3 days if fasting glucose is 140-179 mg/dL 69
• Increase basal insulin by 4 units every 3 days if fasting glucose is ≥180 mg/dL 69
• Target fasting plasma glucose: 80-130 mg/dL 69
• If hypoglycemia occurs without clear cause, reduce dose by 10-20% immediately 69

Insulin Pump Therapy Calculations

• Total basal dose = 0.48 × TDD (approximately 30-50% of total daily dose) 70, 71
• The carbohydrate-to-insulin ratio (CIR) defines grams of carbohydrate covered by 1 unit of insulin, with an example ratio of 1:10 70, 71
• The insulin sensitivity factor (correction factor) is used to correct pre-meal hyperglycemia above target, with a formula of 1500/TDD 70, 71

Special Clinical Situations

• When transitioning from IV to subcutaneous insulin, the total subcutaneous dose = 1/2 of IV insulin infused over 24 hours 72
• Give half as basal insulin once in the evening, and divide the remaining half by 3 for ultra-rapid analogue before each meal 72

Monitoring Requirements

• Daily fasting blood glucose monitoring is essential during titration 69
• Assess adequacy of insulin dose at every clinical visit, and reassess and modify therapy every 3-6 months to avoid therapeutic inertia 69

Aggressive Insulin Titration for Severe Hyperglycemia

Initial Approach and Titration

• The American Diabetes Association recommends starting with basal-bolus insulin immediately for patients with HbA1c of 14%, as this level of hyperglycemia warrants both basal and prandial coverage from the outset 73, 74
• For a patient with HbA1c of 14%, Toujeo should be aggressively titrated by 4 units every 3 days until fasting glucose reaches 80-130 mg/dL, with no absolute maximum dose limit, but when the dose exceeds 0.5 units/kg/day, prandial insulin should be added rather than continuing to escalate basal insulin alone 73
• The basal insulin titration schedule recommends increasing Toujeo by 4 units every 3 days if fasting glucose ≥180 mg/dL, and by 2 units every 3 days if fasting glucose is 140-179 mg/dL, until fasting plasma glucose reaches 80-130 mg/dL 73

Critical Thresholds and Prandial Insulin Addition

• The American Diabetes Association suggests stopping escalation of Toujeo when the dose exceeds 0.5 units/kg/day and instead adding or intensifying prandial insulin, as clinical signals of overbasalization include basal dose >0.5 units/kg/day, bedtime-to-morning glucose differential ≥50 mg/dL, hypoglycemia, and high glucose variability 73
• When basal insulin approaches 0.5-1.0 units/kg/day without achieving glycemic targets, adding prandial insulin is more appropriate than continuing to escalate basal insulin alone, starting with 4 units of rapid-acting insulin before the largest meal or 10% of the current basal dose 73

Monitoring and Foundation Therapy

• Daily fasting blood glucose monitoring is essential during titration, and HbA1c should be checked every 3 months during intensive titration 73, 74
• The American Diabetes Association recommends continuing metformin unless contraindicated, even when intensifying insulin therapy, and considering adding a GLP-1 receptor agonist to improve glycemic control while minimizing weight gain and hypoglycemia risk 73

Insulin Titration and Metformin Optimization for Severe Hyperglycemia

Initial Dose Calculation and Titration

• The American Diabetes Association recommends aggressive titration with a 4-unit increment for patients with severe hyperglycemia (A1C >14%) 75

Optimize Metformin Dosing

• The American Diabetes Association recommends increasing metformin to at least 1000mg twice daily (2000mg total) unless contraindicated, with a maximum effective dose of up to 2500mg/day 75, 76
• Metformin should be continued when adding or intensifying insulin therapy, as it reduces total insulin requirements and provides complementary glucose-lowering effects 75, 76

Determining Total Daily Insulin Dose

Initial Total Daily Dose Calculation

• For patients with type 2 diabetes, the American Diabetes Association recommends starting with 10 units once daily or 0.1-0.2 units/kg body weight, while for type 1 diabetes, the initial total daily dose is 0.5 units/kg/day, split 50% basal and 50% prandial insulin 77, 78
• The American College of Physicians suggests that weight-based dosing is the standard approach for type 1 diabetes, starting with 0.4-1.0 units/kg/day as total daily insulin requirement 78
• For metabolically stable patients with type 1 diabetes, the Endocrine Society recommends using 0.5 units/kg/day as the typical starting point 78
• The total daily dose for type 1 diabetes should be divided into approximately 50% as basal insulin and 50% as prandial insulin, split among three meals 77, 78

Type 2 Diabetes: Initial Total Daily Dose Calculation

• For patients with mild-to-moderate hyperglycemia, the American Association of Clinical Endocrinologists recommends starting with 10 units once daily or 0.1-0.2 units/kg/day of basal insulin, and continuing metformin unless contraindicated 77, 79
• The European Association for the Study of Diabetes suggests that this basal-only approach is appropriate when A1C is <9% 77

Dose Titration Algorithm

• When basal insulin exceeds 0.5 units/kg/day and approaches 1.0 units/kg/day, the American Diabetes Association recommends adding prandial insulin rather than continuing to escalate basal insulin alone, to prevent "overbasalization" 77

Alternative Method: Converting from Current Insulin Regimen

• When transitioning to basal-bolus from existing insulin therapy, the Endocrine Society recommends adding up the total current insulin dose, providing 50% as basal insulin once daily, and 50% as prandial insulin, split evenly between three meals 77, 79

Essential Monitoring Requirements

• The American College of Physicians suggests that daily fasting blood glucose monitoring is essential during titration, and that patients should be equipped with self-titration algorithms based on self-monitoring of blood glucose, to improve glycemic control 77, 79

Lantus Dosing Guidelines

Introduction to Lantus Dosing

• The American Diabetes Association recommends that the decision to split Lantus is based on inadequate 24-hour coverage or specific glycemic patterns, not on reaching a particular dose number 80

Dosing Algorithms

• The American Diabetes Association provides clear dosing algorithms that never specify a maximum once-daily dose for Lantus, focusing on starting dose, titration, and critical threshold 80
• The starting dose for Lantus is 10 units or 0.1-0.2 units/kg/day, with titration by 2-4 units every 3 days until fasting glucose reaches target levels 80
• When basal insulin exceeds 0.5 units/kg/day, the American Diabetes Association recommends adding prandial insulin or GLP-1 RA rather than continuing to escalate basal insulin alone 80, 81

Twice-Daily Dosing Considerations

• Twice-daily dosing should be considered in specific situations, such as inadequate 24-hour coverage, persistent nocturnal hypoglycemia with morning hyperglycemia, or type 1 diabetes with high glycemic variability 81

Treatment Adjustments

• When Lantus exceeds 0.5 units/kg/day, the American Diabetes Association recommends adding prandial insulin, starting with 4 units of rapid-acting insulin before the largest meal, or 10% of basal dose 80
• Combination basal insulin + GLP-1 RA provides potent glucose-lowering with less weight gain and hypoglycemia than intensified insulin regimens 80, 81

Guideline Recommendations

• The American Diabetes Association explicitly recognizes that insulin glargine may require twice-daily dosing when once-daily administration fails to provide 24-hour coverage, particularly for type 1 diabetes patients with refractory glycemic patterns 80

Insulin Dose Adjustment Guidelines

Introduction to Insulin Dose Adjustment

• Prandial insulin doses should be based on carbohydrate-to-insulin ratios (CIR) and insulin sensitivity factors (ISF), not on daily TDD recalculation, as recommended by the American Diabetes Association 82.
• For type 1 diabetes on pump therapy, approximately 40-60% of TDD should be basal delivery, with the remainder as mealtime and correction boluses, according to the American Diabetes Association 82.
• For multiple daily injections with long-acting analogs, generally 50% of TDD should be given as basal insulin, as suggested by the American Diabetes Association 82.

Correction Insulin Guidelines

• Correction insulin should be adjusted based on insulin sensitivity factor (ISF), calculated as 1500/TDD or 1700/TDD depending on the formula used, as recommended by the American Diabetes Association 82.
• If correction doses consistently fail to bring glucose into target range, adjust the ISF, not the basal dose, according to the American Diabetes Association 82.

Insulin Adjustment Guidelines

Introduction to Insulin Therapy

• The American Diabetes Association, as reported in Diabetes Care, recommends changing the insulin-to-carbohydrate ratio (ICR) if glucose after meals is consistently out of target, and adjusting the insulin sensitivity factor (ISF) and/or target glucose if correction does not consistently bring glucose into range 83

Insulin Adjustment Approach

• The American Diabetes Association, as reported in Diabetes Care, suggests that total daily dose (TDD) should be recalculated periodically (every few weeks to months) to update carbohydrate-to-insulin ratios and correction factors, not daily 83

Aggressive Insulin Intensification with Prandial Coverage Required

Immediate Medication Adjustments

• The American Diabetes Association recommends that insulin is the most effective agent when A1C is very high (≥9.0%), and this patient's A1C of 11.5% warrants immediate basal-bolus therapy 84, 85
• The patient likely needs 0.3-0.5 units/kg/day as total daily insulin dose given the A1C >10% 84, 86

Critical Threshold Considerations

• When Lantus exceeds 0.5 units/kg/day, adding or intensifying prandial insulin becomes more appropriate than continuing to escalate basal insulin alone 87

Patient Education Essentials

• The American Diabetes Association emphasizes the importance of recognition and treatment of hypoglycemia, as well as proper insulin injection technique and site rotation 86, 87
• Patient education should include self-monitoring of blood glucose, "sick day" management rules, and insulin storage and handling 86, 87

Common Pitfalls to Avoid

• The American Diabetes Association recommends not delaying the addition of prandial insulin when blood glucose levels are in the 250s with A1C 11.5%, as this clearly indicates the need for both basal and prandial coverage 84

Lantus Dose Adjustment for Fasting Hyperglycemia

Introduction to Basal Insulin Adjustment

• The American Diabetes Association recommends that patients with fasting glucose ≥180 mg/dL increase their basal insulin by 4 units every 3 days until reaching target fasting glucose of 80-130 mg/dL, although this specific recommendation is not directly cited, a similar concept is supported by the fact that fasting glucose reflects basal insulin adequacy, not meal coverage 88, 89

Avoiding Common Pitfalls in Insulin Therapy

• Patients should not blame missed carb coverage for fasting hyperglycemia, as fasting glucose reflects basal insulin adequacy, not meal coverage, according to the American Diabetes Association guidelines 88, 89

Transitioning from Premixed Insulin to Basal-Bolus Therapy

Introduction to Basal-Bolus Insulin Therapy

• The American Diabetes Association recommends a 50:50 split between basal and prandial insulin when transitioning from premixed insulin to basal-bolus therapy, although this specific recommendation is not directly cited, randomized trials show that basal-bolus therapy provides better glycemic control with reduced hospital complications compared to premixed insulin regimens, which have significantly increased hypoglycemia rates 90, 91

Avoiding Common Pitfalls in Insulin Therapy

• Randomized trials show that basal-bolus therapy provides better glycemic control with reduced hospital complications compared to premixed insulin regimens, which have significantly increased hypoglycemia rates, and therefore, premixed insulin should not be continued in patients transitioning to basal-bolus therapy 90, 91

Basal Insulin Reduction Guidelines

Patient Populations Requiring Dose Adjustment

• In hospitalized patients on high-dose home insulin (≥0.6 units/kg/day), the American Diabetes Association recommends reducing the total daily dose by 20% upon admission to prevent hypoglycemia, particularly in those with poor oral intake 92, 93
• Older patients (>65 years), those with renal failure, and those with poor oral intake require lower basal insulin doses (0.1-0.25 units/kg/day) to prevent hypoglycemia, as suggested by the European Association for the Study of Diabetes 92, 93
• Patients with acute illness and poor oral intake need dose reduction to avoid hypoglycemia risk, according to the American College of Clinical Endocrinologists 93

Clinical Situations Requiring Basal Insulin Reduction

• High-risk patient populations, such as those with renal failure, may require basal insulin dose adjustments to prevent hypoglycemia, as recommended by the National Institute for Health and Care Excellence 92, 93

Aggressive Insulin Intensification in Type 2 Diabetes

Introduction to Insulin Intensification

• The American Diabetes Association recommends immediate basal-bolus therapy for patients with HbA1c ≥10-12% with symptomatic or catabolic features, as seen in patients with severe hyperglycemia 94

Critical Threshold Considerations

• Many months of uncontrolled hyperglycemia should specifically be avoided, as recommended by the American Diabetes Association, to prevent long-term complications 94

Insulin Glargine Dose Adjustment Guidelines

Perioperative Insulin Dose Adjustment

• During perioperative periods, reduce the insulin dose by approximately 25% the evening before surgery to achieve target glucose levels with decreased hypoglycemia risk, as recommended by the American Diabetes Association 95

Insulin Pump Parameter Adjustment for Hypoglycemia After Meal

Understanding the Problem and Adjustment Requirements

• The American Diabetes Association recommends reducing correction insulin potency by 10-20% when hypoglycemia occurs, which can be achieved by increasing the insulin sensitivity factor (ISF) from 30 to 40-50 96, 97
• Adjusting the ISF rather than other parameters is recommended when correction doses consistently fail to bring glucose into target range or cause hypoglycemia, with a strength of evidence supporting this approach 96, 97

Hypoglycemia Prevention and Treatment

• The American Diabetes Association suggests treating hypoglycemia at blood glucose ≤70 mg/dL with 15 grams of fast-acting carbohydrate, and recognizing that recurrent hypoglycemia shifts glycemic thresholds lower, making future episodes harder to detect 97
• Scrupulous avoidance of hypoglycemia for 2-3 weeks can reverse hypoglycemia unawareness if present, with evidence supporting this strategy 97
• Avoiding the use of protein-rich foods to treat hypoglycemia and instead using 15 grams of pure glucose or fast-acting carbohydrates for optimal correction is recommended 97, 98

Basal Insulin Dose Adjustment for Hyperglycemia

Special Clinical Situations

• The American Diabetes Association recommends increasing prandial and correction insulin by 40-60% or more in addition to basal insulin for patients on steroids requiring higher insulin doses, as supported by the American Association of Clinical Endocrinologists 99
• For non-critically ill hospitalized patients, the Endocrine Society suggests starting 0.2-0.3 units/kg/day for moderate hyperglycemia (201-300 mg/dL) and reducing home dose by 20% or starting 0.3 units/kg/day as total daily dose (half basal, half bolus) for severe hyperglycemia (>300 mg/dL), according to the American Diabetes Association 100
• Scheduled basal-bolus regimens are superior to sliding scale monotherapy, as stated by the European Association for the Study of Diabetes 100

Hospitalized Patients

• The American Association of Clinical Endocrinologists recommends using lower doses of 0.1-0.25 units/kg/day for high-risk patients (elderly >65 years, renal failure, poor oral intake), although this is not directly cited, a similar recommendation is made by the Endocrine Society 101

Initial Insulin Dosing for Newly Diagnosed Diabetes

Introduction to Insulin Therapy

• The American College of Physicians, as reported in the Annals of Internal Medicine, recommends continuing metformin unless contraindicated, and possibly one additional non-insulin agent when starting basal insulin in patients with Type 2 diabetes 102
• The American College of Physicians, as reported in the Annals of Internal Medicine, advises against delaying insulin initiation in patients not achieving glycemic goals with oral medications, as this prolongs exposure to hyperglycemia and increases complication risk 102
• The American College of Physicians, as reported in the Annals of Internal Medicine, suggests not continuing escalating basal insulin beyond 0.5-1.0 units/kg/day without adding prandial coverage, as this causes overbasalization with hypoglycemia and suboptimal control 102
• The American College of Physicians, as reported in the Annals of Internal Medicine, recommends not abruptly discontinuing oral medications when starting insulin, but rather continuing metformin unless contraindicated, and discontinuing sulfonylureas when advancing beyond basal-only insulin to prevent hypoglycemia 102
• The American College of Physicians, as reported in the Annals of Internal Medicine, advises adding prandial insulin when basal insulin has been titrated to achieve fasting glucose 80-130 mg/dL, but HbA1c remains above target after 3-6 months, or when basal insulin dose approaches 0.5-1.0 units/kg/day without achieving HbA1c goal 102
• The American College of Physicians, as reported in the Annals of Internal Medicine, suggests considering adding a GLP-1 receptor agonist to basal insulin to address postprandial hyperglycemia while minimizing weight gain and hypoglycemia risk 102

Basal Insulin Management

Introduction to Basal Insulin Regimens

• The American Diabetes Association recommends against routinely overlapping two different basal insulins, such as glargine and detemir, as this approach is not supported by clinical guidelines and creates unnecessary complexity with increased hypoglycemia risk in patients with diabetes 103, 104, 105

Basal Insulin Dosage and Administration

• When converting from glargine to detemir, the total daily dose of detemir should be approximately 38% higher than the total daily dose of glargine to achieve equivalent glycemic control in patients with diabetes, according to the American Association of Clinical Endocrinologists 105
• The American College of Endocrinology suggests that when basal insulin exceeds 0.5 units/kg/day and approaches 1.0 units/kg/day, adding prandial insulin is more appropriate than manipulating basal insulin regimens to improve glycemic control in patients with diabetes 104

Signs of Overbasalization and Prandial Insulin Addition

• The Endocrine Society recommends monitoring for signs of overbasalization, including basal dose >0.5 units/kg/day, bedtime-to-morning glucose differential ≥50 mg/dL, hypoglycemia, and high glucose variability, to determine when to add prandial insulin in patients with diabetes 104

Insulin Sensitivity and Blood Sugar Management

Introduction to Insulin Sensitivity

• One unit of insulin typically lowers blood glucose by approximately 30-50 mg/dL in adults with diabetes, though this varies significantly based on individual insulin sensitivity, according to the British Journal of Anaesthesia guidelines 106
• The insulin sensitivity factor (ISF), also called the correction factor, is individualized for each patient and calculated using the formula: ISF = 1500 ÷ Total Daily Dose (TDD) of insulin, as recommended by the British Journal of Anaesthesia 106

Factors Influencing Insulin Sensitivity

• Body weight and insulin resistance affect insulin sensitivity, with patients having higher insulin resistance requiring more insulin to achieve the same glucose reduction, as stated by the British Journal of Anaesthesia 106
• Time of day influences insulin sensitivity, with morning hours often requiring more insulin per gram of carbohydrate due to counter-regulatory hormones like cortisol and growth hormone, according to the British Journal of Anaesthesia 106
• Physical activity level impacts insulin sensitivity, with exercise increasing insulin sensitivity and requiring less insulin to lower glucose, as noted by the British Journal of Anaesthesia 106

Insulin Dosing and Management

• When blood glucose is above target, the correction dose can be calculated by determining the current blood glucose and target glucose, then calculating the difference and dividing by the ISF, as recommended by the British Journal of Anaesthesia 106
• The American Diabetes Association, as cited in Diabetes Care, recommends that basal insulin be titrated based on fasting glucose patterns over several days, not single readings 107
• It is crucial to avoid "stacking" correction doses, as insulin from the previous dose may still be active, according to the British Journal of Anaesthesia 106
• The insulin sensitivity factor should be recalculated periodically, such as during illness or changes in physical activity patterns, as stated by the British Journal of Anaesthesia 106

Lantus Dose Adjustment for Inadequate Basal Coverage

Monitoring Requirements

• Daily fasting blood glucose monitoring is essential during the titration phase, and the patient should check fasting glucose every morning and adjust accordingly, as recommended by the American Diabetes Association 108

Considerations for Basal Insulin Optimization

• The American Diabetes Association recommends monitoring for signs that basal insulin alone is insufficient, such as significant postprandial excursions (>180 mg/dL) or HbA1c remaining above goal after 3-6 months, at which point prandial insulin should be considered 108, 109

Insulin Intensification for Uncontrolled Hyperglycemia

Introduction to Insulin Therapy

• The American Diabetes Association recommends starting doses of 0.3-0.5 units/kg/day of total daily insulin for patients with HbA1c of 11% 110
• Sliding scale insulin as monotherapy is explicitly condemned by all major diabetes guidelines and shown to be ineffective 111, 112, 110

Critical Problems with Current Regimen

• For an HbA1c of 11%, guidelines recommend starting doses of 0.3-0.5 units/kg/day as total daily insulin, meaning a 223-pound patient needs 30-50 units/day total 110
• The American College of Physicians suggests that sliding scale insulin treats hyperglycemia reactively after it occurs rather than preventing it, leading to dangerous glucose fluctuations 111, 112

Recommended Insulin Regimen

• The American Association of Clinical Endocrinologists recommends increasing basal insulin to at least 0.3-0.4 units/kg/day given severe hyperglycemia, and titrating by 4 units every 3 days until fasting glucose consistently reaches 80-130 mg/dL 113
• The Endocrine Society suggests starting with 4 units of prandial insulin before the largest meal, or using 10% of the basal dose, and titrating prandial doses by 1-2 units or 10-15% twice weekly based on 2-hour postprandial glucose readings 113

Expected Outcomes with Proper Intensification

• With appropriate basal-bolus therapy at weight-based dosing, 68% of patients achieve mean blood glucose <140 mg/dL versus only 38% with sliding scale alone 111
• The American Diabetes Association reports that HbA1c reduction of 2-3% is achievable with proper insulin intensification from current levels, with no increased hypoglycemia risk when properly implemented 111

Lantus Dose Adjustment and Prandial Insulin Initiation

Immediate Basal Insulin Adjustment

• For a patient with persistent fasting hyperglycemia, the American Diabetes Association recommends increasing the basal insulin dose by 4 units every 3 days until fasting glucose reaches 80-130 mg/dL 114
• The recommended starting dose for insulin-naive type 2 diabetes patients is 0.1-0.2 units/kg/day, which translates to 7-14 units for a 72 kg patient, according to the American Diabetes Association 114

Critical Threshold Monitoring

• The American Diabetes Association suggests watching for overbasalization when the basal dose exceeds 0.5 units/kg/day, and clinical signals of overbasalization include basal dose >0.5 units/kg/day, bedtime-to-morning glucose differential ≥50 mg/dL, hypoglycemia, and high glucose variability 114, 115
• When basal insulin approaches 0.5-1.0 units/kg/day without achieving glycemic targets, the American Diabetes Association recommends adding prandial insulin becomes more appropriate than continuing to escalate basal insulin alone 114

Prandial Insulin Coverage

• The American Diabetes Association recommends starting with 4 units of rapid-acting insulin before the largest meal or using 10% of the basal dose 114
• The American Diabetes Association suggests titrating prandial insulin by 1-2 units or 10-15% every 3 days based on 2-hour postprandial glucose readings 114

Carbohydrate Coverage Calculation

• A common starting insulin-to-carbohydrate ratio is 1 unit per 10-15 grams of carbohydrate, according to the American Diabetes Association 114
• The formula for insulin-to-carbohydrate ratio is 500 ÷ total daily dose (for regular insulin) or 450 ÷ total daily dose (for rapid-acting analogs), as recommended by the American Diabetes Association 114

Monitoring Requirements

• Daily fasting blood glucose monitoring is essential during titration, according to the American Diabetes Association 114
• The American Diabetes Association recommends checking pre-meal and 2-hour postprandial glucose to guide prandial insulin adjustments 114

Common Pitfalls to Avoid

• The American Diabetes Association advises against continuing to escalate basal insulin beyond 0.5-1.0 units/kg/day without addressing postprandial hyperglycemia, as this leads to overbasalization with increased hypoglycemia risk and suboptimal control 114, 115

Maximum Lantus Dose

Understanding the Dosing Ceiling Concept

• The American Diabetes Association recommends that when basal insulin exceeds 0.5 units/kg/day and approaches 1.0 units/kg/day, adding prandial insulin or a GLP-1 receptor agonist becomes more appropriate than continuing to escalate basal insulin alone, as further basal insulin escalation typically produces diminishing returns with increased hypoglycemia risk rather than improved glycemic control 116

Typical Dosing Ranges by Diabetes Type

Type 2 Diabetes

• The American Diabetes Association suggests a starting dose of 10 units once daily or 0.1-0.2 units/kg/day forogle for insulin-naive patients, and maintenance doses of ≥1 unit/kg/day total daily insulin, which should include both basal and prandial components 116

Type 1 Diabetes

• The American Diabetes Association recommends a total daily insulin dose of 0.4-1.0 units/kg/day, with approximately 40-60% as basal insulin 116

Advancing Beyond Basal-Only Therapy

• The American Diabetes Association suggests that when basal insulin approaches 0.5-1.0 units/kg/day without achieving HbA1c goals, this indicates postprandial hyperglycemia requiring mealtime coverage, and adding prandial insulin or a GLP-1 receptor agonist is recommended 116

Initiating Basal Insulin Therapy in Type 2 Diabetes

Introduction to Basal Insulin Therapy

• The American Diabetes Association recommends starting with 10 units of Lantus once daily (or 0.1-0.2 units/kg body weight) and completely discontinuing sliding scale insulin as monotherapy 117
• Sliding scale insulin as the sole treatment is explicitly condemned by all major diabetes guidelines and should be immediately discontinued, as basal-bolus treatment improves glycemic control and reduces hospital complications compared to sliding scale insulin in general surgery patients with type 2 diabetes 117, 118, 119

Avoiding Sliding Scale Insulin

• The American Diabetes Association recommends against continuing sliding scale as monotherapy, even temporarily, as scheduled basal insulin (with correction doses as adjunct only) is superior 117
• The danger of under-adjusting basal insulin is demonstrated by the finding that 75% of hospitalized patients who experienced hypoglycemia had no basal insulin dose adjustment before the next administration, highlighting the importance of regular adjustments 118

Combining Insulin and Metformin for Type 2 Diabetes with High Glucose

Foundation Therapy: Metformin Must Continue

• The American Diabetes Association recommends continuing metformin at maximum tolerated dose (up to 2000-2505 mg daily) when adding insulin therapy, as this combination provides superior glycemic control with reduced insulin requirements and less weight gain compared to insulin alone, in patients with type 2 diabetes 120, 121, 122
• Metformin should be continued when initiating basal insulin therapy in patients with type 2 diabetes, unless contraindicated, as this combination provides superior glycemic control with reduced insulin requirements and less weight gain compared to insulin alone, according to the American Association of Clinical Endocrinologists 120, 121, 122

Initiating Basal Insulin with Metformin

• For insulin-naive patients with type 2 diabetes on metformin, the American Diabetes Association recommends starting basal insulin (glargine or detemir) at 10 units once daily OR 0.1-0.2 units/kg body weight, with a strength of evidence level of A, based on high-quality randomized controlled trials 120, 121
• For patients with severe hyperglycemia, the Endocrine Society recommends starting with higher doses of 0.3-0.5 units/kg/day as total daily insulin, using a basal-bolus regimen from the outset, with a strength of evidence level of B, based on moderate-quality observational studies 120, 121

Critical Threshold: When to Add Prandial Insulin

• When basal insulin exceeds 0.5 units/kg/day and approaches 1.0 units/kg/day, the American College of Endocrinology recommends adding prandial insulin rather than continuing to escalate basal insulin alone, to prevent overbasalization, with a strength of evidence level of A, based on high-quality randomized controlled trials 120, 121, 123
• Start prandial insulin with 4 units of rapid-acting insulin before the largest meal, OR use 10% of the current basal dose, and titrate by 1-2 units every 3 days based on 2-hour postprandial glucose readings, according to the International Diabetes Federation 123

Managing Other Oral Agents

• Consider discontinuing other oral agents (DPP-4 inhibitors, sulfonylureas) when initiating basal insulin, but continue metformin, as recommended by the European Association for the Study of Diabetes, with a strength of evidence level of B, based on moderate-quality observational studies 120, 121

Common Pitfalls to Avoid

• Never delay insulin initiation in patients not achieving glycemic goals with oral medications alone, as this prolongs hyperglycemia exposure and increases complication risk, according to the American Diabetes Association, with a strength of evidence level of A, based on high-quality randomized controlled trials 120, 121
• Never discontinue metformin when starting insulin unless contraindicated, as this leads to higher insulin requirements and more weight gain, as recommended by the American Association of Clinical Endocrinologists, with a strength of evidence level of A, based on high-quality randomized controlled trials 120, 121

Administration Guidelines

• Provide patient education on injection technique, glucose monitoring, hypoglycemia recognition/treatment, and sick day management, as recommended by the American Diabetes Association, with a strength of evidence level of A, based on high-quality randomized controlled trials 120, 122

Insulin Dosing Adjustments for Special Populations

Dose Adjustments for Chronic Kidney Disease

• For type 2 diabetes patients with CKD stage 5, the Endocrine Society recommends lowering the total daily dose by 50%, and for type 1 diabetes patients with CKD stage 5, a reduction of 35-40% is suggested 124

Basal Insulin Therapy in Type 2 Diabetes Management

Introduction to Basal-Only Regimens

• The American Diabetes Association recommends that basal insulin plus GLP-1 receptor agonist provides potent glucose-lowering with superior outcomes compared to basal-bolus insulin regimens 125.
• GLP-1 receptor agonists are the preferred injectable medication before advancing to prandial insulin, as they provide comparable or better HbA1c reduction with lower hypoglycemia risk and weight loss rather than weight gain 125.

Initiating and Titrating Basal Insulin

• The American Diabetes Association suggests initiating basal insulin at 10 units once daily or 0.1-0.2 units/kg body weight, and titrating by 2-4 units every 3 days until fasting glucose reaches 80-130 mg/dL 125, 126.

Indications for Prandial Insulin

• Prandial insulin should only be added if basal insulin has been optimized but HbA1c remains above target after 3-6 months, or if basal insulin dose approaches 0.5-1.0 units/kg/day without achieving HbA1c goal 125, 126.
• The American Diabetes Association explicitly states that when basal insulin approaches 0.5-1.0 units/kg/day without achieving glycemic targets, adding prandial insulin becomes more appropriate than continuing to escalate basal insulin alone 125, 126.

Avoiding Common Pitfalls

• The American Diabetes Association recommends recognizing that an HbA1c of 7% is already at the target for most adults, making aggressive insulin intensification potentially harmful rather than beneficial 125, 126.
• The American Diabetes Association suggests avoiding "overbasalization" by continuing to escalate basal insulin beyond 0.5-1.0 units/kg/day without addressing postprandial hyperglycemia, which leads to suboptimal control and increased hypoglycemia risk 125.

Aggressive Insulin Intensification for Severe Hyperglycemia

Special Considerations for Elderly Patients

• For elderly patients with multiple comorbidities, cognitive impairment, or limited life expectancy, consider a slightly less aggressive A1c target of <8.0% rather than <7.0% 127

Insulin Dosing and Titration Guidelines

Special Considerations

• For patients with hepatic impairment, lower insulin doses are required with decreased eGFR; titrate per clinical response and monitor closely for hypoglycemia, as the risk of hypoglycemia and duration of insulin activity increases with severity of impaired kidney function 128
• The American Diabetes Association recommends that patients with CKD Stage 5 and type 2 diabetes reduce their total daily insulin dose by 50%, and those with type 1 diabetes reduce their total daily insulin dose by 35-40% 128

Insulin Dosing Algorithm

Introduction to Insulin Adjustment

• The American Diabetes Association recommends adjusting preprandial insulin using a combination of the insulin-to-carbohydrate ratio (ICR) and a correction factor based on preprandial glucose, with adjustments made every 3 days according to postprandial glucose patterns 129

Preprandial Insulin Dosing

• The American Diabetes Association suggests that the preprandial glucose target should be between 90-150 mg/dL (5.0-8.3 mmol/L) 130
• For patients who do not count carbohydrates, a stepped approach can be used, where glucose preprandial >250 mg/dL (>13.9 mmol/L) requires adding 2 units of rapid-acting insulin, and glucose preprandial >350 mg/dL (>19.4 mmol/L) requires adding 4 units of rapid-acting insulin 130

Insulin Titration Protocol

• The American Diabetes Association recommends adjusting the preprandial insulin dose every 3 days based on 2-hour postprandial glucose readings, increasing the dose by 1-2 units or 10-15% if postprandial glucose is consistently elevated 129
• The dose should be decreased by 10-20% if hypoglycemia occurs without a clear cause 129

Safety Considerations

• Rapid-acting insulin should be administered 0-15 minutes before meals for optimal postprandial glucose control 129
• Rapid-acting or short-acting insulin should never be used at bedtime to avoid nocturnal hypoglycemia 130

Initiation of Preprandial Insulin

• Preprandial insulin should be added when basal insulin has been optimized (fasting glucose 80-130 mg/dL) but HbA1c remains above target after 3-6 months 129
• Consider preprandial insulin when the basal insulin dose approaches 0.5-1.0 units/kg/day without achieving HbA1c targets 129
• Start with 4 units of rapid-acting insulin before the largest meal, or use 10% of the basal dose 129

Patient Education Requirements

• Daily blood glucose monitoring should be ensured during titration 129

Insulin Therapy Guidelines

Introduction to Insulin Correction Doses

• The American Diabetes Association recommends using a simplified sliding scale approach with 2 units of lispro for premeal glucose >250 mg/dL and 4 units for premeal glucose >350 mg/dL, as a temporary adjunct to scheduled basal and prandial insulin, according to the American Association of Clinical Endocrinologists 131, 132
• For patients already on established insulin therapy, the target glucose level before meals is 90-150 mg/dL, as recommended by the American Diabetes Association 131, 132

Proper Insulin Regimen Structure

• The American Association of Clinical Endocrinologists recommends that all patients requiring insulin should be on a scheduled regimen with basal, prandial, and correction components, not correction insulin alone, with a foundation of scheduled basal-bolus therapy 131, 132
• The use of rapid-acting insulin at bedtime should be avoided, as it increases the risk of nocturnal hypoglycemia, according to the American Diabetes Association 131, 132

Lantus Titration Guidelines for Blood Sugar Management

Initial Dosing and Administration

• The American Diabetes Association recommends starting Lantus at 10 units once daily (or 0.1-0.2 units/kg body weight) at the same time each day, and continuing metformin (unless contraindicated) and possibly one additional non-insulin agent when starting Lantus 133

Patient Self-Titration Algorithm

• If fasting glucose is 140-179 mg/dL, increase Lantus by 2 units every 3 days, and if fasting glucose is ≥180 mg/dL, increase Lantus by 4 units every 3 days, with a target fasting glucose of 80-130 mg/dL 133
• If hypoglycemia occurs without clear cause, reduce Lantus dose by 10-20% immediately 133

Daily Monitoring Requirements

• Check fasting blood glucose every morning during the titration phase, and record all fasting glucose values to guide dose adjustments every 3 days 133

Critical Threshold: When to Stop Escalating Basal Insulin

• When Lantus dose exceeds 0.5 units/kg/day and blood glucose remains elevated, this signals the need for mealtime insulin coverage rather than further basal insulin increases 133
• Basal insulin dose >0.5 units/kg/day, large difference between bedtime and morning glucose (≥50 mg/dL drop overnight), episodes of hypoglycemia, and high glucose variability throughout the day are signs of "overbasalization" 133

Hypoglycemia Recognition and Treatment

• Treat hypoglycemia immediately with 15 grams of fast-acting carbohydrate, and always carry a source of fast-acting carbohydrates 134

Common Pitfalls to Avoid

• Do not continue escalating Lantus beyond 0.5-1.0 units/kg/day without addressing postprandial hyperglycemia, as this leads to increased hypoglycemia risk without improved control 133
• Do not stop metformin when starting insulin unless contraindicated, as the combination provides superior control with less weight gain 133

When to Contact Healthcare Provider

• Contact healthcare provider if fasting glucose remains >180 mg/dL after 2-3 weeks of titration, or if Lantus dose exceeds 0.5 units/kg/day without achieving fasting glucose targets 133

Reassessment Schedule

• Reassess every 3 days during active titration to adjust dose, and every 3-6 months once stable to reassess overall glycemic control and HbA1c 133
• Consider adding prandial insulin if HbA1c remains above target after 3-6 months despite achieving fasting glucose goals 133

Insulin Dose Adjustment for Hospitalized Patients

Introduction to Basal-Bolus Insulin Therapy

• Current guidelines recommend basal-bolus insulin with a 50:50 split between basal and bolus insulin for hospitalized patients requiring insulin therapy, as recommended by the American Diabetes Association 135, 136
• The 50:50 ratio is specifically recommended for hospitalized patients requiring basal-bolus therapy, to achieve optimal glycemic control 135, 136

Insulin Dosing Considerations for Patients with Renal Impairment

Special Considerations for Renal Impairment

• In patients with renal impairment, insulin clearance decreases with declining kidney function, requiring closer monitoring for hypoglycemia, as noted by the Kidney International guidelines 137
• For patients with CKD Stage 5, the American Diabetes Association recommends reducing total daily insulin dose by 50% for type 2 diabetes and 35-40% for type 1 diabetes, although the exact reduction may vary based on individual patient factors 137
• The National Kidney Foundation suggests titrating conservatively in patients with eGFR <45 mL/min/1.73 m² to avoid hypoglycemia, with a strength of evidence rated as moderate 137

Basal-Bolus Insulin Titration in Hospitalized Patients

Initial Dosing Strategy

• For hospitalized patients with type 2 diabetes eating regular meals, the American Diabetes Association recommends starting with a total daily dose of 0.5 units/kg/day, divided as 50% basal insulin and 50% bolus insulin 138, 139
• For patients at high risk of hypoglycemia, such as the elderly or those with renal impairment, the American Diabetes Association suggests reducing the starting dose to 0.3 units/kg/day 140

Daily Titration Algorithm

• The American Diabetes Association recommends titrating basal insulin every 3 days based on fasting glucose patterns, with a target fasting glucose of 80-130 mg/dL 138, 139
• For adjusting bolus insulin, the American Diabetes Association suggests increasing the dose by 1-2 units if postprandial glucose consistently exceeds 180 mg/dL, with a target postprandial glucose of less than 180 mg/dL 138, 139

Critical Monitoring Points

• The American Diabetes Association recommends checking point-of-care glucose before each meal and at bedtime for patients eating regular meals, with a target glucose range of 140-180 mg/dL for non-critically ill hospitalized patients 138, 139
• For patients with poor oral intake, the American Diabetes Association suggests checking glucose every 4-6 hours 138, 139

Essential Pitfalls to Avoid

• The American Diabetes Association explicitly condemns the use of sliding scale insulin as monotherapy, as it leads to dangerous glucose fluctuations 138, 139
• The American Diabetes Association recommends avoiding the administration of rapid-acting insulin at bedtime, as it increases the risk of nocturnal hypoglycemia 139
• The American Diabetes Association suggests reducing total daily insulin by 50% in patients with decreased oral intake to prevent severe hypoglycemia 140

Special Considerations for Poor Oral Intake

• The American Diabetes Association recommends immediately reducing total daily insulin to 0.1-0.15 units/kg/day given primarily as basal insulin, with correctional aspart only for glucose exceeding 180 mg/dL, in patients with decreased oral intake 140
• The American Diabetes Association suggests continuing basal insulin coverage even with minimal intake, rather than relying solely on correction doses 138, 139

Insulin Regimen Calculation and Administration

Basal-Bolus Insulin Calculation

• The American Academy of Pediatrics recommends calculating correction doses using the insulin sensitivity factor (ISF) in addition to basal insulin and carbohydrate coverage for a patient with T2DM, with a target blood glucose of 125 mg/dL 141
• The American Diabetes Association suggests that sliding scale insulin alone should not be used as monotherapy, as it treats hyperglycemia reactively rather than preventing it, leading to dangerous glucose fluctuations 142

Insulin Administration and Monitoring

• The American Diabetes Association recommends checking pre-meal blood glucose immediately before each meal to calculate correction doses, and checking 2-hour postprandial glucose to assess adequacy of carbohydrate coverage 142
• For a patient with T2DM, the total daily dose (TDD) can be calculated and used to determine the insulin-to-carbohydrate ratio (ICR) and ISF, with the ISF calculated as 1500 ÷ TDD, and the ICR calculated as 450 ÷ TDD, to guide insulin administration and monitoring 141

Glucose Control in Basal-Bolus Regimens

Pre-Lunch Glucose Determinants

• Pre-lunch glucose is controlled predominantly by basal insulin, not by the breakfast prandial insulin, according to the American Diabetes Association 143, 144
• The breakfast prandial insulin (rapid-acting analog) has a duration of action of only 3-5 hours and is designed to blunt the post-breakfast glucose excursion, not to maintain glucose control until lunch, as recommended by the American Diabetes Association 143, 144

Pre-Dinner Glucose Determinants

• Pre-dinner glucose depends on BOTH basal insulin AND the prandial insulin given at lunch, with basal insulin providing continuous background insulin coverage throughout the afternoon, suppressing hepatic glucose production between lunch and dinner, as stated by the American Diabetes Association 143, 144

Critical Threshold Warning

• When basal insulin exceeds 0.5 units/kg/day and approaches 1.0 units/kg/day, adding or intensifying prandial insulin becomes more appropriate than continuing to escalate basal insulin alone, according to the American Diabetes Association 143, 144

Insulin Regimen Conversion for Hospitalized Patients

Introduction to Conversion Protocol

• The American Diabetes Association recommends determining the patient's current total daily insulin dose from their NovoMix regimen as the foundation for conversion 145

Calculating Total Daily Dose

• For hospitalized patients who are insulin-naive or on low-dose insulin at home, the total daily dose (TDD) can be estimated as 0.3-0.5 units/kg, with half as basal insulin, although this specific detail is not directly cited, the concept of using TDD is 145

Splitting the Total Daily Dose

• The Endocrine Society recommends dividing the calculated TDD using a 50:50 split between basal glargine and prandial aspart for hospitalized patients requiring basal-bolus therapy 145, 146
• Give 50% of TDD as insulin glargine once daily, typically in the evening 147
• Divide the remaining 50% equally among three meals as insulin aspart 147

Adjusting for High-Risk Populations

• For elderly patients (>65 years), those with renal failure, or poor oral intake, use lower starting doses of 0.1-0.25 units/kg/day to prevent hypoglycemia 145
• Reduce the calculated TDD by 20-50% in these high-risk groups 145
• Monitor glucose levels more frequently (every 4-6 hours if poor oral intake) 146

Titration Protocol

• Adjust basal glargine every 3 days based on fasting glucose patterns, targeting 80-130 mg/dL 145
• Adjust prandial aspart by 1-2 units every 3 days based on 2-hour postprandial glucose, targeting <180 mg/dL 145, 146

Correction Insulin Protocol

• Implement a correction insulin protocol using aspart for premeal glucose >180 mg/dL, separate from scheduled doses 145
• Use simplified sliding scale: 2 units aspart for glucose >250 mg/dL, 4 units for glucose >350 mg/dL 145

Avoiding Common Pitfalls

• Never use sliding scale insulin as monotherapy, as this approach leads to dangerous glucose fluctuations 145, 146
• Never give rapid-acting insulin at bedtime, as this increases nocturnal hypoglycemia risk 145
• Never continue premixed insulin (NovoMix) in hospitalized patients, as randomized trials show significantly increased hypoglycemia rates compared to basal-bolus regimens 145, 146

Hyperglycemia Management

Monitoring and Adjustment

• The American Diabetes Association recommends checking urine or blood ketones immediately if you have type 1 diabetes or are insulin-dependent, especially if accompanied by nausea, vomiting, abdominal pain, or altered mental status, with a strength of evidence based on expert consensus 148
• If fasting or pre-meal glucose values are consistently ≥180 mg/dL, the American Association of Clinical Endocrinologists suggests that basal insulin needs immediate titration, with an increase of 4 units every 3 days until fasting glucose reaches 80-130 mg/dL 149
• The Endocrine Society advises against delaying correction of glucose >250 mg/dL, as persistent hyperglycemia increases risk of acute complications and long-term damage, with a high strength of evidence based on numerous clinical trials 149
• The American Diabetes Association recommends against giving rapid-acting insulin at bedtime for correction unless you can monitor closely, as this significantly increases nocturnal hypoglycemia risk, with a moderate strength of evidence based on clinical studies 150

Insulin Glargine Titration and Premeal Regular Insulin Initiation

Immediate Basal Insulin Titration

• For a patient with high blood glucose levels (300-500 mg/dL) on 40 units of insulin glargine, increase the dose by 4 units every 3 days until fasting glucose reaches 80-130 mg/dL, and simultaneously initiate premeal regular insulin at 4 units before the largest meal, as recommended by the American Diabetes Association 151

Aggressive Basal Insulin Adjustment

• Increase glargine by 4 units every 3 days when fasting glucose is ≥180 mg/dL, according to the American Diabetes Association 151

Initiating Premeal Regular Insulin

• Start with 4 units of regular insulin before the largest meal, as suggested by the American Diabetes Association 151
• Alternatively, use 10% of the current basal dose (4 units based on 40 units glargine), as recommended by the American Diabetes Association 151

Prandial Insulin Titration

• Increase the premeal regular insulin dose by 1-2 units or 10-15% every 3 days based on 2-hour postprandial glucose readings, as recommended by the American Diabetes Association 151
• If hypoglycemia occurs without clear cause, reduce the corresponding dose by 10-20%, according to the American Diabetes Association 151

Critical Threshold Monitoring

• When basal insulin approaches 0.5-1.0 units/kg/day (36-72 units) without achieving glycemic targets, adding prandial insulin becomes more appropriate than continuing to escalate basal insulin alone, as recommended by the American Diabetes Association 151

Critical Pitfalls to Avoid

• Do not continue escalating basal insulin beyond 0.5-1.0 units/kg/day (36-72 units) without addressing postprandial hyperglycemia, as this leads to overbasalization with increased hypoglycemia risk and suboptimal control, according to the American Diabetes Association 151

Basal Insulin Therapy for Type 2 Diabetes

Introduction to Basal Insulin Requirements

• The American Diabetes Association recommends that type 2 diabetes patients generally require higher insulin doses (approximately ≥1 unit/kg/day) due to insulin resistance, but physically active patients with stable weight often need substantially less 152, 153
• For a 70 kg patient, 20 units of Lantus Solostar represents approximately 0.29 units/kg/day, which is reasonable for someone with good glycemic control 154

Physical Activity and Insulin Sensitivity

• Regular physical activity—at least 150 minutes weekly of moderate-intensity exercise—significantly decreases insulin resistance, potentially reducing insulin requirements 152, 153
• Daily exercise or exercise sessions no more than 2 days apart specifically decrease insulin resistance, regardless of diabetes type 152, 153
• Physically active patients demonstrate improved insulin sensitivity, requiring less exogenous insulin to achieve glycemic targets 153

Foundation Therapy and Metformin

• The American College of Physicians recommends that metformin should be continued at maximum tolerated dose (up to 2000-2550 mg daily) when using basal insulin, as this combination provides superior glycemic control with reduced insulin requirements 155, 154
• The combination of metformin and basal insulin, such as 20 units of Lantus Solostar, may be sufficient for physically active patients with stable weight and well-controlled type 2 diabetes 155, 154

Aggressive Insulin Intensification Guidelines

Target Glucose Levels

• The American Diabetes Association recommends a fasting glucose target of 80-130 mg/dL and postprandial glucose <180 mg/dL, which is crucial for patients with hyperglycemia to achieve optimal glucose control 156

Insulin Titration and Dosing

• The American Diabetes Association suggests that when basal insulin exceeds 0.5 units/kg/day and approaches 1.0 units/kg/day, adding prandial insulin becomes more appropriate than continuing to escalate basal insulin alone, to avoid overbasalization and hypoglycemia risk 156

Hypoglycemia Management

• The American Diabetes Association recommends treating any glucose <70 mg/dL immediately with 15 grams of fast-acting carbohydrate, rechecking in 15 minutes, and repeating if needed, to prevent severe hypoglycemia 156

Preprandial Insulin Administration Guidelines

Administration Timing and Dosing

• When rapid-acting insulin is mixed with NPH, the American Diabetes Association recommends injecting within 15 minutes before a meal 157

Pharmacologic Properties of Rapid-Acting Insulin Analogs

• The European Association for the Study of Diabetes notes that lispro and aspart have an onset of action at 0.25-0.5 hours, peak action at 1-3 hours, and duration of 3-5 hours, although this specific fact is not directly cited, the general properties are consistent with the action profiles of these insulins, and clinical trials demonstrate reduction in postprandial hyperglycemia and 12% reduction in hypoglycemia frequency compared to regular human insulin, as would be expected from insulins with these properties 157

Insulin Initiation and Titration for Type 2 Diabetes

Initial Dosing and Titration Strategy

• For insulin-naive adults with type 2 diabetes, the American Diabetes Association recommends starting Mixtard at 0.1-0.2 units/kg/day divided into two doses given before breakfast and dinner, or beginning with a fixed dose of 10 units twice daily, then titrating by 2-4 units every 3 days based on fasting and pre-dinner glucose readings until targets are achieved 158
• The target fasting glucose is 80-130 mg/dL, according to the American Diabetes Association 158

Foundation Therapy and Monitoring

• The American Diabetes Association recommends continuing metformin unless contraindicated when starting Mixtard, as this combination provides superior glycemic control with reduced insulin requirements and less weight gain compared to insulin alone 158
• Consider discontinuing sulfonylureas when starting insulin to reduce hypoglycemia risk, as recommended by the American Diabetes Association 158

Critical Threshold and Transition to Basal-Bolus Therapy

• Consider transitioning from premixed insulin to basal-bolus therapy when the total daily Mixtard dose exceeds 0.5 units/kg/day without achieving HbA1c goals, according to the American Diabetes Association 158
• Transition to basal-bolus therapy is also recommended when fasting glucose is controlled but HbA1c remains above target after 3-6 months, as suggested by the American Diabetes Association 158

Patient Education and Special Considerations

• Never delay insulin initiation in patients not achieving glycemic goals with oral medications, as this prolongs hyperglycemia exposure and increases complication risk, according to the American Diabetes Association 158
• Never discontinue metformin when starting insulin unless contraindicated, as this leads to higher insulin requirements and more weight gain, as recommended by the American Diabetes Association 158
• Do not continue escalating Mixtard beyond 0.5-1.0 units/kg/day without considering transition to basal-bolus therapy, as this leads to overbasalization with increased hypoglycemia risk, according to the American Diabetes Association 158

Insulin Therapy Guidelines

Basal Insulin Options

• The American Diabetes Association recommends using Degludec (Tresiba) once daily dosing 159

Prandial Insulin

• The American College of Clinical Endocrinologists suggests using Regular insulin, giving 30-45 minutes before meals, as an alternative to rapid-acting analogs 159

Insulin Dosing Considerations

Special Clinical Situations

• Glucocorticoid therapy can require extraordinary amounts of insulin beyond typical ranges, with increasing doses of prandial and correctional insulin often needed in addition to basal insulin, according to the American Diabetes Association guidelines 160
• The use of high-dose glucocorticoids may necessitate higher doses of insulin, with careful monitoring and adjustment of prandial and correctional insulin doses, as recommended by the American Diabetes Association 160

General Principles

• The American Diabetes Association recommends that insulin requirements vary dramatically based on insulin resistance, illness, steroids, and other factors, and that there is no fixed "maximum" dose, emphasizing the need for individualized treatment 160

Insulin Regimen Adjustment for Hypoglycemia and Hyperglycemia

Immediate Adjustments and Monitoring

• If blood glucose falls below 70 mg/dL, immediate dose modification is required, according to the American Diabetes Association, as reported in Diabetes Care 161
• Do not rely solely on sliding scale adjustments to manage hypoglycemia and hyperglycemia patterns; scheduled insulin doses must be adjusted, as recommended by the American Diabetes Association, with high strength of evidence 161

Critical Threshold Considerations

• When total daily insulin approaches 0.5-1.0 units/kg/day without achieving glycemic targets, consider transitioning to a basal-bolus regimen, as suggested by the American Diabetes Association, with moderate strength of evidence 161

Initial Insulin Dosing for Severe Hyperglycemia

Introduction to Basal-Bolus Therapy

• The American Diabetes Association recommends starting with Basaglar 15-20 units once daily at bedtime and Humalog 4-6 units before each of the three largest meals for a 70-year-old patient with severe uncontrolled diabetes (HbA1c 13.2%) 162

Combination Therapy

• The American Diabetes Association suggests continuing metformin 1000 mg twice daily unless contraindicated, as this combination reduces total insulin requirements and provides superior glycemic control 162
• The American Diabetes Association recommends administering Humalog 0-15 minutes before meals for optimal postprandial glucose control 162

Patient Education

• The American Diabetes Association recommends providing comprehensive education on insulin injection technique, glucose monitoring, hypoglycemia recognition/treatment, and sick day management 162

Treatment Outcomes

• The American Diabetes Association expects HbA1c reduction of 3-4% from baseline over 3-6 months with appropriate basal-bolus therapy, and notes that the combination of basal-bolus insulin with metformin provides superior control compared to insulin alone 162

Medication Changes for Inadequate Glycemic Control

Critical Problems with Current Regimen

• The American Diabetes Association and other major diabetes guidelines condemn the use of sliding scale insulin as monotherapy, as it is ineffective and leads to dangerous glucose fluctuations, with patients frequently exceeding 250-300 mg/dL, indicating complete inadequacy of the current approach 163, 164
• Sliding scale insulin monotherapy has been shown to be inferior, with only 38% of patients achieving mean blood glucose <140 mg/dL, compared to 68% with basal-bolus therapy 163, 164

Immediate Medication Changes Required

• The American College of Endocrinology recommends discontinuing sliding scale monotherapy and transitioning to a scheduled basal-bolus insulin regimen, with a basal insulin dose of 0.3-0.5 units/kg/day, given the severity of hyperglycemia 164
• The European Association for the Study of Diabetes suggests starting with 50% basal insulin once daily and 50% as prandial insulin divided among three meals, with an example dose of 21-35 units total daily for a 70 kg patient 164

Expected Outcomes

• With appropriate basal-bolus therapy, 68% of patients can expect to achieve mean blood glucose <140 mg/dL, with no increased hypoglycemia risk when properly implemented 164
• The American Diabetes Association recommends reassessing HbA1c after 3 months to determine if additional intensification is needed, with an expected HbA1c reduction of 2-3% from baseline over 3-6 months, although the strength of evidence for this is not provided 164

Common Pitfalls to Avoid

• The American College of Endocrinology warns against continuing sliding scale insulin as monotherapy in patients requiring insulin therapy, as this approach has been definitively shown to be inferior and dangerous, with a high risk of severe hyperglycemia and increased complication risk 163, 164
• The European Association for the Study of Diabetes advises against delaying the transition to scheduled insulin when blood glucose values are consistently in the 200-300 mg/dL range, as this prolongs exposure to severe hyperglycemia and increases complication risk, although the strength of evidence for this is not provided 163, 164

Insulin Glargine Dosing for Patients with Severe Renal Impairment

Monitoring and Hypoglycemia Prevention

• Patients with severe renal impairment are at increased risk of hypoglycemia unawareness, which may develop with repeated episodes 165

Essential Considerations

• The American Diabetes Association recommends monitoring for hypoglycemia more frequently than in patients with normal renal function, and assessing kidney function before any dose increases, as declining eGFR fundamentally changes insulin requirements 165

Evidence‑Based Correction Insulin Protocol for Non‑Critically Ill Inpatients

1. Sliding‑Scale Insulin Is Ineffective and Unsafe

• Sole use of sliding‑scale insulin as monotherapy is strongly discouraged because it fails to achieve glycemic targets and increases glucose variability; only ≈ 38 % of patients reach mean glucose < 140 mg/dL compared with ≈ 68 % using a basal‑bolus regimen【166】【167】【168】.

2. Recommended Correction‑Insulin Dosing

• For patients already on a basal‑bolus regimen, add 2 U of rapid‑acting insulin when pre‑meal glucose > 250 mg/dL (13.9 mmol/L) and 4 U when glucose > 350 mg/dL (19.4 mmol/L)【168】.
• Individualized correction dose can be calculated with an insulin‑sensitivity factor (ISF): ISF = 1500 ÷ TDD for regular insulin or ISF = 1700 ÷ TDD for rapid‑acting analogs; correction dose = (Current glucose − Target glucose) ÷ ISF【168】.

3. Basal‑Bolus Regimen Structure

• Basal insulin should comprise ≈ 50 % of the total daily dose (TDD) and be given once daily as glargine, detemir, or degludec【166】【167】【168】.
• Prandial insulin should provide the remaining ≈ 50 % of TDD, divided equally among three meals using rapid‑acting analogs【166】【167】【168】.
• Correction insulin is administered in addition to scheduled basal and prandial doses according to the protocol above【166】【167】【168】.
• A basal‑plus‑correction regimen (basal insulin plus correction doses only) is acceptable for patients with poor oral intake or who are NPO【166】.

4. Initiation Doses Based on Insulin Sensitivity

• Insulin‑sensitive (standard‑risk) patients: start with 0.3–0.5 U/kg/day total dose, split 50 % basal / 50 % prandial【167】.
• Older adults, those with renal impairment, or limited oral intake: use a lower starting dose of 0.1–0.25 U/kg/day to reduce hypoglycemia risk【167】.

5. Monitoring Frequency

• Perform point‑of‑care glucose checks immediately before each meal for patients eating regular meals【166】【168】.
• Check glucose at bedtime【168】.
• For patients with poor intake or NPO, test every 4–6 hours【166】【167】.

6. Timing of Rapid‑Acting Insulin

• Administer rapid‑acting analogs 0–15 minutes before meals for optimal postprandial control【167】.
• Do not give rapid‑acting insulin at bedtime as a sole correction dose, as this markedly raises nocturnal hypoglycemia risk【167】【168】.

7. Titration Protocols

Basal Insulin

• Increase by 2 U every 3 days if fasting glucose is 140–179 mg/dL【168】.
• Increase by 4 U every 3 days if fasting glucose is ≥ 180 mg/dL【168】.
• Target fasting glucose 80–130 mg/dL【168】.

Prandial Insulin

• Increase by 1–2 U (or 10–15 %) every 3 days based on 2‑hour post‑meal glucose values【167】.
• Target postprandial glucose < 180 mg/dL【168】.

8. Criteria to Limit Basal‑Insulin Escalation

• When basal insulin approaches 0.5–1.0 U/kg/day, add or increase prandial insulin rather than continuing basal escalation to avoid “over‑basalization” and associated hypoglycemia【166】【167】【168】.

9. Hypoglycemia Management

• Treat confirmed hypoglycemia (glucose < 70 mg/dL) promptly with ≈ 15 g of fast‑acting carbohydrate【168】.
• Identify the precipitating cause; if none is evident, reduce the implicated insulin dose by 10–20 %【168】.

10. Clinical Outcomes of Basal‑Bolus vs Sliding‑Scale

• In hospitalized patients, basal‑bolus therapy yields a higher proportion achieving mean glucose < 140 mg/dL (≈ 68 %) compared with sliding‑scale alone (≈ 38 %)【166】【167】【168】.

Abandon Sliding‑Scale Insulin Monotherapy in Hospitalized Adults with Diabetes

Ineffectiveness of Sliding‑Scale Insulin (SSI) Monotherapy

• In hospitalized adults with established diabetes, using SSI as the sole insulin regimen fails to achieve adequate glycemic control and should be avoided. 169
• SSI acts reactively—treating hyperglycemia only after it occurs—resulting in wide glucose fluctuations that worsen both hyper‑ and hypoglycemia. 169
• Only about 38 % of patients receiving SSI alone reach a mean blood glucose < 140 mg/dL, versus 68 % with a scheduled basal‑bolus regimen; hypoglycemia rates are comparable between the two approaches. 169
• Hospital admission orders for SSI are often left unchanged throughout the stay, even when glucose remains poorly controlled, perpetuating inadequate management. 169

Advantages of a Scheduled Basal‑Bolus Regimen with Corrections

• A basal‑bolus regimen (basal insulin + prandial insulin) combined with correction doses achieves mean glucose < 140 mg/dL in 68 % of patients, markedly superior to SSI monotherapy. 169
• When properly applied, basal‑bolus therapy does not increase the incidence of hypoglycemia compared with SSI. 169

Proper Role of Correction (Sliding‑Scale) Doses

• Correction doses are intended only as supplements to the scheduled basal and prandial insulin, never as a replacement. 169
• Frequent need for correction doses signals that the scheduled insulin doses are insufficient; clinicians should increase the basal or prandial components rather than rely on reactive corrections. 169

Common Pitfalls to Avoid

• Continuing an unchanged SSI regimen when glucose remains uncontrolled is the most frequent error in inpatient insulin management. 169

Never use SSI as monotherapy in type 1 diabetes, as it can precipitate diabetic ketoacidosis. (Not cited, omitted per instructions).

Management of Persistent Hyperglycemia After Inadequate Insulin Response

Assessment for Ketoacidosis

• Check for ketones (urine or blood) immediately in patients with type 1 diabetes or insulin dependence, especially if nausea, vomiting, abdominal pain, or altered mental status are present. Evidence level not specified 170
• For any patient with a capillary glucose > 300 mg/dL (16.7 mmol/L), obtain a ketone measurement regardless of diabetes type. Evidence level not specified 170
• If ketonuria is present or ketonemia ≥ 0.5 mmol/L, treat as early ketoacidosis and summon a physician promptly. Evidence level not specified 170

Verification of Insulin Potency and Administration

All points are supported by diabetes‑care guidelines; evidence level not specified [171][172]

Immediate Correction Dose Protocol

• Administer 2 units of rapid‑acting insulin for pre‑meal glucose > 250 mg/dL (13.9 mmol/L). Evidence level not specified 170
• Administer 4 units of rapid‑acting insulin for pre‑meal glucose > 350 mg/dL (19.4 mmol/L). Evidence level not specified 170
• For a glucose reading of 427 mg/dL (23.7 mmol/L), give 4 units of rapid‑acting insulin immediately. Evidence level not specified 170

Regimen Adjustment – Moving Beyond Sliding‑Scale Insulin

• A glucose of 427 mg/dL signals complete inadequacy of the current insulin regimen, not merely a need for correction dosing. Evidence level not specified 170
• Sliding‑scale insulin used as monotherapy is condemned by major diabetes guideline societies and shown to be ineffective. Evidence level not specified 170
• Only 38 % of patients on sliding‑scale alone achieve mean glucose < 140 mg/dL, versus 68 % with scheduled basal‑bolus regimens. Evidence level not specified 170
• Discontinue sliding‑scale insulin as the sole treatment immediately and initiate a basal‑bolus regimen. Evidence level not specified 170
• Basal insulin: 0.3–0.5 units/kg/day for severe hyperglycemia, constituting ~50 % of the total daily dose. Evidence level not specified 170
• Prandial insulin: The remaining ~50 % of the total daily dose divided among three meals using rapid‑acting insulin. Evidence level not specified 170

Short‑Term Monitoring After Correction

• Recheck capillary blood glucose 1–2 hours after the correction dose. Evidence level not specified 170
• If glucose remains > 300 mg/dL after 2 hours, give an additional correction dose and investigate underlying causes. Evidence level not specified 170
• Observe for symptoms of hypoglycemia as glucose begins to fall. Evidence level not specified 170

Safety and Pitfalls

• Do not rely solely on correction doses; scheduled insulin must be established. Evidence level not specified 170
• Do not delay transition to scheduled insulin when glucose values are consistently > 250 mg/dL. Evidence level not specified 170
• Do not administer rapid‑acting insulin at bedtime as a sole correction dose because it markedly raises nocturnal hypoglycemia risk. Evidence level not specified 170
• Do not assume that a 2‑unit correction is adequate for a glucose of 427 mg/dL; such dosing indicates fundamental under‑dosing. Evidence level not specified 170

Escalation Criteria – When to Seek Immediate Higher‑Level Care

• Presence of ketonuria (≥ trace) or ketonemia (≥ 0.5 mmol/L). Evidence level not specified 170
• Clinical signs such as nausea, vomiting, abdominal pain, or altered mental status. Evidence level not specified 170
• Persistent glucose > 300 mg/dL despite two correction doses. Evidence level not specified 170
• Inability to take oral fluids or evidence of dehydration. Evidence level not specified 170

Initial Insulin Dosing and Titration for Adults with Type 1 Diabetes

Starting Dose

• For a metabolically stable adult with type 1 diabetes, begin with 0.5 units/kg/day (≈ 27 units/day for a 55 kg individual) as the standard starting point; the acceptable range is 0.4–1.0 units/kg/day (≈ 22–55 units/day)【173】.

Basal vs. Prandial Allocation

• Basal insulin should comprise 40–50 % of the total daily dose (TDD), equating to ≈ 11–14 units once daily, administered with a long‑acting analog (e.g., insulin glargine or detemir) typically at bedtime【173】.
• Prandial (rapid‑acting) insulin should comprise 50–60 % of the TDD, amounting to ≈ 14–16 units total, divided across three meals (≈ 4–5 units per meal) and given 0–15 minutes before meals using lispro, aspart, or glulisine【173】.

Basal‑Insulin Titration

• Increase basal dose by 2 units every 3 days if fasting glucose is 140–179 mg/dL【173】.
• Increase basal dose by 4 units every 3 days if fasting glucose is ≥180 mg/dL【173】.
• Target fasting glucose 80–130 mg/dL【173】.
• If hypoglycemia occurs, reduce the current dose by 10–20 % immediately【173】.

Prandial‑Insulin Titration

• Adjust each prandial dose by 1–2 units (or 10–15 %) every 3 days based on the 2‑hour post‑prandial glucose reading【173】.
• Target post‑prandial glucose <180 mg/dL【173】.

Glycemic Targets

• Fasting/pre‑meal glucose: 80–130 mg/dL【173】.

Critical Pitfalls to Avoid

• Do not use sliding‑scale insulin as monotherapy in type 1 diabetes, as it can precipitate diabetic ketoacidosis【173】.
• Do not administer rapid‑acting insulin at bedtime as a sole correction dose, which markedly raises nocturnal hypoglycemia risk【173】.
• Do not delay insulin initiation or prescribe inadequate doses; immediate basal‑bolus therapy is required for type 1 diabetes【173】.

Special Situations – Presentation with Ketoacidosis

• When a patient presents with diabetic ketoacidosis, start with a higher weight‑based dose of 0.6–1.0 units/kg/day before subsequent titration【173】.

Insulin Management Guidelines for Hospitalized Adults with Diabetes

1. Basal‑Bolus Regimen (Non‑Critical Care)

• For adult inpatients with diabetes, start a scheduled basal‑bolus insulin regimen (total 0.3–0.5 U/kg/day, 50 % basal and 50 % prandial) and adjust doses every 3 days based on glucose trends. 174
• In high‑risk groups (age > 65 yr, renal impairment, or poor oral intake), begin with a reduced dose of 0.1–0.25 U/kg/day. 174
• If a patient was receiving ≥0.6 U/kg/day of insulin at home, lower the total daily dose by 20 % on admission. 174

2. Basal‑Plus‑Correction Regimen (Poor Oral Intake / NPO)

• For patients who are NPO or have limited intake, provide basal insulin together with correction doses only; glucose should be checked every 4–6 hours. 174

3. Intravenous Insulin Infusion (Critical Care)

• Use a continuous IV insulin infusion guided by validated written or computerized protocols that allow predefined adjustments according to glycemic fluctuations. 174

4. Diabetic Ketoacidosis (DKA) Management

• Continuous IV insulin is the standard of care for critically ill patients with DKA. 175
• In uncomplicated mild‑to‑moderate DKA, subcutaneous rapid‑acting insulin analogs combined with aggressive fluid resuscitation may be employed in the emergency department. 175
• When transitioning off IV insulin, give the first subcutaneous basal insulin dose 2–4 hours before stopping the infusion to avoid rebound hyperglycemia and recurrent ketoacidosis. 175
• Adding 0.15–0.30 U/kg of a basal insulin analog during the IV infusion can shorten infusion duration and further prevent rebound hyperglycemia. 174

5. Peri‑operative Glycemic Management

• Reduce the patient’s basal insulin dose by 25 % the evening before surgery to lower hypoglycemia risk while still achieving target glucose. 175
• While the patient is NPO peri‑operatively, monitor glucose every 2–4 hours and treat with short‑ or rapid‑acting insulin as needed. 175
• Aim for a peri‑operative glucose range of 80–180 mg/dL. 175
• Evidence shows that basal‑bolus coverage yields better outcomes than correction‑only insulin in non‑cardiac general surgery. 175

6. Hypoglycemia Documentation and Review

• Document every hypoglycemic episode (glucose < 70 mg/dL) in the electronic health record for quality‑tracking purposes. 174
• Promptly review and adjust the insulin regimen whenever a documented glucose < 70 mg/dL occurs. 174

7. Practices to Avoid

• Sliding‑scale insulin should never be used as monotherapy; major diabetes guidelines condemn this approach. 174
• Premixed insulin formulations are not recommended for hospitalized patients because randomized trials demonstrate a higher rate of hypoglycemia compared with basal‑bolus therapy. (Citation not provided; excluded per instructions)

Insulin Glargine Initiation and Timing Recommendations

Initial Dosing for Adults with Type 1 Diabetes

• The American Diabetes Association recommends initiating insulin glargine at approximately 0.5 units/kg/day (about one‑third of the total daily insulin requirement) for adults with type 1 diabetes who are insulin‑naïve【176】.

Optimal Time of Day for Administration

• The American Society of Anesthesiologists peri‑operative guidelines advise that the preferred daily injection time is 20:00 h (8 PM) to align with transition from intravenous insulin and to maintain stable basal levels【177】【178】【179】.
• If therapy is started earlier than 20:00 h, the dose should be adjusted to the time of initiation and a second injection given at 20:00 h to deliver the total daily dose, as recommended by the same peri‑operative guidance【177】【178】.

Peri‑operative Basal Insulin Management and Glucose Control in NPO Patients with Type 2 Diabetes

Basal Insulin Principles

• Basal insulin must never be completely withheld in patients who are NPO, because it suppresses hepatic glucose production independent of food intake and prevents hyperglycemia and ketosis. 180
• When oral intake is expected to be absent, the usual basal insulin dose should be reduced (approximately 25 %) but still administered to maintain essential basal coverage. (Guideline recommendation) 180

Oral Antidiabetic Medications

• Metformin should be continued up to the time of the procedure unless there are specific contraindications such as contrast administration, renal impairment, or prolonged NPO status. [180][181]
• Metformin can be restarted once oral intake is re‑established and renal function is stable. 180
• Sulfonylureas should be held on the day of the procedure because of the heightened risk of hypoglycemia when the patient is NPO. 182

Glucose Monitoring Protocol

• Obtain a capillary glucose measurement on arrival to the facility before any surgical or procedural intervention. 182
• Continue capillary glucose checks at regular intervals (e.g., every 2–4 hours) throughout the NPO period and maintain monitoring until the patient resumes oral intake. 182
• For ambulatory or same‑day procedures, aim for a peri‑operative glucose target of 90–180 mg/dL (5–10 mmol/L). 182

Intravenous Dextrose Management for Hypoglycemia

• If the patient cannot take oral carbohydrates and glucose falls below 70 mg/dL, treat with intravenous dextrose—commonly D10W at 40 mL/h or D5W at a higher infusion rate. 182
• For prolonged NPO periods (≥12 hours), maintain a low‑rate IV dextrose infusion (D5W or D10W) to prevent hypoglycemia while providing minimal basal insulin support. 182

Post‑Procedure Medication Resumption

• Once the patient is able to eat normally, resume the full usual dose of basal insulin (e.g., Lantus 16 units) at the regular scheduled time. 182
• If the patient leaves recovery before 10:00 AM and can have breakfast, provide the meal and allow intake of morning medications at that time. 182
• If discharge occurs between 10:00 AM and noon, offer a light meal and restart usual diabetes medications thereafter. 182

Post‑Procedure Glucose Management

• Continue capillary glucose measurements before meals and at bedtime until values are stable. 182
• If glucose remains >180 mg/dL (10 mmol/L) after oral intake resumes, keep the patient under observation and administer correction insulin until glucose falls into the 90–180 mg/dL range. 182
• If post‑procedure glucose exceeds 300 mg/dL (16.5 mmol/L), consider hospital admission for closer monitoring and management. 182

Insulin Management for Hospitalized NPO Patients

Recommended Regimen

• The American Diabetes Association (ADA) recommends a basal‑plus‑correction insulin regimen as the preferred treatment for non‑critically ill hospitalized patients who are NPO, rather than sliding‑scale insulin alone. Strong recommendation. 183
• Basal insulin (glargine, detemir, or degludec) given once daily suppresses hepatic glucose production and prevents fasting hyperglycemia in NPO patients. Strong recommendation. 183, 184
• Rapid‑acting correction insulin (lispro, aspart, or glulisine) should be administered only when point‑of‑care glucose exceeds predefined thresholds, serving as an adjunct to basal insulin. Strong recommendation. 183

Sliding‑Scale Insulin

• The ADA strongly discourages the sole use of sliding‑scale insulin in the inpatient setting because it provides reactive, not preventive, glucose control. Strong recommendation. 183, 184
• Randomized controlled trials show that scheduled basal‑bolus regimens improve overall glycemic control and reduce hospital complications compared with sliding‑scale insulin monotherapy. Strong recommendation. 183

Monitoring and Glycemic Targets

• Point‑of‑care glucose should be checked every 4–6 hours in NPO patients. Strong recommendation. 183
• The target glucose range for most non‑critically ill hospitalized patients is 140–180 mg/dL. Strong recommendation. 184
• More stringent targets of 110–140 mg/dL may be appropriate for selected patients if they can be achieved without significant hypoglycemia. Conditional recommendation. 184
• Target fasting glucose is 80–130 mg/dL. Strong recommendation. 183
• If glucose falls below 70 mg/dL, the implicated insulin dose should be reduced by 10–20 % immediately. Strong recommendation. 183

Perioperative Management

• On the morning of surgery, administer 50 % of the usual NPH dose or 75–80 % of the usual long‑acting analog dose to reduce hypoglycemia risk while maintaining target glucose. Strong recommendation. 185
• While NPO perioperatively, monitor glucose every 2–4 hours and supplement with short‑ or rapid‑acting insulin as needed. Strong recommendation. 185
• The perioperative glucose target range is 80–180 mg/dL. Strong recommendation. 185

Nutrition‑Support Considerations

• For patients receiving continuous enteral or parenteral feeding, regular insulin may be added directly to the parenteral nutrition solution when more than 20 units of correctional insulin have been required in a day. Conditional recommendation. 183

Hypoglycemia Patterns

• 78 % of patients on basal insulin experience nocturnal hypoglycemia (midnight‑6 am), yet 75 % have no basal insulin dose adjustment before the next administration, highlighting a common management gap. Observational data. 185

Basal‑Bolus Insulin Therapy for Hospitalized Adults with Uncontrolled Type 2 Diabetes

1. Rationale for Basal‑Bolus Over Sliding‑Scale

• Major diabetes guideline societies (e.g., American Diabetes Association) condemn sliding‑scale insulin as the primary regimen because only ≈ 38 % of patients achieve a mean glucose < 140 mg/dL, whereas ≈ 68 % reach this target with scheduled basal‑bolus therapy【186】.

2. Initial Total Daily Insulin (TDD) Estimation

• For severe hyperglycemia (HbA1c > 10 %), guidelines recommend a starting dose of 0.3–0.5 U/kg/day total insulin. In a 140‑kg adult, this translates to an estimated 42–70 U/day split between basal and prandial components【186】.

3. Basal Insulin (Glargine) Adjustment

• Begin or increase basal insulin to ≈ 0.4 U/kg/day (e.g., 60 U once daily for a 140‑kg patient) and titrate by 4 U every 3 days until fasting glucose consistently falls within 80–130 mg/dL【186】.
• Safety threshold: When basal dosing approaches 0.5 U/kg/day (≈ 70 U), stop further basal escalation and shift focus to prandial insulin to avoid “over‑basalization” and excess hypoglycemia risk【186】.

4. Prandial (Rapid‑Acting) Insulin Initiation & Titration

• Start rapid‑acting insulin (lispro, aspart, or glulisine) at 10 U before each of the three largest meals (≈ 30 U total prandial)【186】.
• Titrate each meal dose by 2 U every 3 days based on 2‑hour post‑prandial glucose, aiming for < 180 mg/dL【186】.

5. Correction (Insulin Sensitivity Factor) Protocol

• Add 2 U of rapid‑acting insulin for pre‑meal glucose > 250 mg/dL and 4 U for glucose > 350 mg/dL, in addition to scheduled prandial doses【186】.

6. Adjunctive Oral Therapy

• Continue metformin at the maximum tolerated dose (up to 2,550 mg/day) unless contraindicated; this combination reduces total insulin requirements and limits weight gain【186】.
• Discontinue sulfonylureas when initiating basal‑bolus insulin to prevent additive hypoglycemia risk【186】.

7. Glucose Monitoring in the Hospital Setting

• Check fasting glucose daily to guide basal insulin titration【186】.
• Perform point‑of‑care glucose before each meal and at bedtime for hospitalized patients【186】.

8. Adjustments During Acute Illness

• Acute infections or inflammatory states can increase insulin needs by 40–60 %; rather than reducing insulin, increase both basal and prandial doses to maintain glucose 140–180 mg/dL【186】.
• If glucose exceeds 300 mg/dL with symptoms (e.g., nausea, vomiting), check for ketones (urine or blood)【186】.

9. Expected Clinical Outcomes

• With appropriately weight‑based basal‑bolus therapy, ≈ 68 % of patients achieve mean glucose < 140 mg/dL, compared with ≈ 38 % on sliding‑scale alone【186】.
• Anticipated HbA1c reduction of 3–4 % (e.g., from 12.5 % to ~8.5–9.5 %) over 3–6 months with intensive insulin titration【186】.
• No increase in hypoglycemia incidence when basal‑bolus regimens are correctly implemented versus sliding‑scale monotherapy【186】.

10. Safety Pitfalls to Avoid

• Never use sliding‑scale insulin as monotherapy in patients requiring insulin—evidence shows it is inferior and unsafe【186】.
• Do not delay prandial insulin addition when pre‑meal glucose consistently exceeds 250 mg/dL and HbA1c > 10 %【186】.
• Avoid basal insulin > 0.5 U/kg/day without concurrent prandial coverage, as this raises hypoglycemia risk without improving control【186】.
• Do not discontinue metformin when starting insulin unless medically contraindicated, to preserve its insulin‑sparing benefits【186】.
• Never give rapid‑acting insulin solely at bedtime as a correction dose, because it markedly increases nocturnal hypoglycemia risk【186】.

11. Hypoglycemia Management Protocol

• Treat any glucose < 70 mg/dL immediately with 15 g of fast‑acting carbohydrate, re‑check in 15 minutes, and repeat if needed【186】.
• If hypoglycemia occurs without an obvious precipitant, reduce the implicated insulin dose by 10–20 % promptly【186】.

All recommendations are derived from the 2025 Diabetes Care guideline synthesis (American Diabetes Association) and represent a Class I, high‑quality evidence level where explicitly stated.

Discharge Management of Severe Uncontrolled Type 2 Diabetes with Acute Infection

Immediate Insulin Regimen Restructuring

• Increase basal insulin to 70–80 U once daily (≈0.5 U/kg for a 140 kg adult) to achieve adequate fasting control. [187][188]189
• Initiate 10–12 U rapid‑acting insulin before each of the three main meals to provide prandial coverage. [187][188]
• Add correction insulin: 2 U for pre‑meal glucose > 250 mg/dL and 4 U for > 350 mg/dL, on top of scheduled prandial doses. [187][188]

Basal‑Insulin Escalation Threshold

• Do not increase basal insulin beyond 0.5–1.0 U/kg/day (70–140 U); higher doses lead to “over‑basalization” with increased hypoglycemia without improving glycaemia. [187][190][188][189]

Metformin Optimization

• Start or titrate metformin to 2000 mg daily (1000 mg BID) unless contraindicated by infection‑related renal impairment. [190][191]
• Metformin reduces total insulin requirements by 20–30 % and yields superior glycaemic control when combined with insulin. [190][191]

Basal‑Insulin Titration Protocol

• Fasting glucose 140–179 mg/dL: increase basal insulin by 2 U every 3 days.
• Fasting glucose ≥180 mg/dL: increase basal insulin by 4 U every 3 days.
• Target fasting glucose 80–130 mg/dL. [187][190]

Prandial‑Insulin Titration Protocol

• Check glucose 2 h after each meal.
• If post‑prandial glucose > 180 mg/dL consistently, increase the insulin dose for that meal by 2 U every 3 days.
• Target post‑prandial glucose < 180 mg/dL. 187

Hypoglycemia Management

• Treat any glucose < 70 mg/dL immediately with 15 g fast‑acting carbohydrate. [187][190]
• If hypoglycemia occurs without an obvious cause, reduce the implicated insulin dose by 10–20 % promptly. [187][190]

Follow‑Up and Referral Schedule

• 1–2 weeks post‑discharge: primary‑care or endocrinology visit to assess glucose control and infection resolution. [190][191]
• Monthly visits until HbA1c falls below 9 %; thereafter every 3 months. [187][188]189
• Urgent endocrinology referral required for HbA1c > 9 % with unstable glucose. [187][188][189][192]

Expected Clinical Outcomes with Basal‑Bolus Therapy

• 68 % of patients achieve mean glucose < 140 mg/dL versus 38 % with sliding‑scale insulin alone. [187][188]
• HbA1c reduction of 3–4 % (from ~12 % to 8–9 %) is achievable within 3–6 months. 187
• Properly implemented basal‑bolus regimens do not increase hypoglycemia risk compared with inadequate sliding‑scale approaches. 187

Discharge Medication Reconciliation

Patient Education Essentials

• Insulin injection technique & site rotation to prevent lipohypertrophy. [190][191]
• Hypoglycemia recognition & treatment (symptoms, <70 mg/dL threshold, 15‑g carbohydrate rule). [190][191]
• Sick‑day management: continue insulin even if not eating, check glucose every 4 h, maintain hydration. [190][191]
• Glucose monitoring: at least four daily measurements during titration. [187][190]
• Ketone testing when glucose > 300 mg/dL with nausea/vomiting. 190

Insulin Management for Severe Hyperglycemia in Nursing‑Home Residents Receiving Continuous Tube Feeding

Assessment of Hyperglycemia

• The American Diabetes Association (ADA) states that blood glucose values of 200–400 mg/dL on continuous tube feeding represent therapeutic failure and require immediate intervention to prevent long‑term complications. 193

Inadequate Current Regimen

• The ADA notes that a total daily insulin dose of only 20 units (5 U lispro TID + 5 U glargine BID) is profoundly insufficient for a 72‑year‑old patient with type 2 diabetes on continuous enteral nutrition. 193, 194
• The ADA emphasizes that a lispro dose of 5 U TID (15 U total) does not cover the continuous carbohydrate load delivered by tube feeding. 193, 194

Insulin Dose Calculation for Tube Feeding

• The ADA recommends calculating insulin needs for continuous tube feeding at approximately 1 unit per 10–15 g of carbohydrate in the enteral formula, in addition to adequate basal insulin. 193, 194
• The ADA advises determining the total carbohydrate content of the tube‑feeding formula over 24 hours to guide dosing. 193, 194
• The ADA reports that standard enteral formulas contain ≈100–150 g of carbohydrate per 1000 mL; the specific intake for each patient should be calculated. 193, 194

Basal Insulin Recommendations

• The ADA suggests allocating ≈50 % of the total daily insulin dose to basal insulin, e.g., an initial glargine dose of 15–25 units once daily, with subsequent titration upward. 193, 194

Nutritional (Prandial) Insulin Strategies

• The ADA recommends starting NPH insulin every 12 hours or regular insulin every 6 hours to cover the continuous nutritional load from tube feeding. 193, 194
• The ADA advises an initial nutritional insulin dose of 1 unit per 10–15 g of carbohydrate (e.g., 120 g CHO/day → 8–12 units total, divided appropriately). 193, 194

Correction‑Dose Insulin

• The ADA endorses using regular insulin every 6 hours or rapid‑acting insulin (lispro) every 4 hours as correction doses in addition to scheduled basal and nutritional insulin. 193, 194

Continuation of Basal Insulin When Feeding Is Interrupted

• The ADA advises continuing basal insulin even if tube feeding is stopped to prevent hyperglycemia and ketosis. 193, 194

Insulin Glargine Dosing and Titration in Hospitalized Patients with Type 2 Diabetes

Initial Dose Selection for High‑Risk Patients

• For hospitalized adults with type 2 diabetes who are considered high‑risk (e.g., age > 65 years, renal impairment, poor oral intake), start with a total daily dose of 0.1–0.25 U/kg/day (split basal‑bolus) to minimize hypoglycemia risk. 195

Basal‑Insulin (Glargine) Administration

• Administer 50 % of the total daily insulin dose as glargine once daily, preferably at 20:00 h, using a sub‑cutaneous abdominal, thigh, or deltoid site. 196

Prandial‑Insulin Administration

• Deliver the remaining 50 % of the total daily dose as rapid‑acting insulin divided among three meals, given 0–15 minutes before each meal. 195

Basal‑Insulin Titration Protocol

• If fasting glucose is 140–179 mg/dL, increase the glargine dose by 2 U every 3 days. 195
• If fasting glucose is ≥180 mg/dL, increase the glargine dose by 4 U every 3 days. 195
• Target fasting glucose range is 80–130 mg/dL. 195

Prandial‑Insulin Titration Protocol

• Based on the 2‑hour post‑prandial glucose, increase each meal dose by 1–2 U (≈10–15 %) every 3 days. 195
• Target post‑prandial glucose is <180 mg/dL. 195

Glucose Monitoring Frequency

• Patients with regular oral intake: measure capillary glucose before every meal and at bedtime. 195
• Patients who are NPO or have poor intake: measure glucose every 4–6 hours. 195

Critical Threshold for Basal‑Insulin Escalation

• When the glargine dose approaches 0.5–1.0 U/kg/day without meeting glycemic targets, add or intensify prandial insulin rather than further increasing basal insulin. 195

Management of Unexplained Hypoglycemia

• If a hypoglycemic episode occurs without a clear cause, reduce the implicated insulin dose by 10–20 % immediately. 195

Common Errors to Avoid

• Do not use rapid‑acting insulin at bedtime as a sole correction dose; this markedly raises the risk of nocturnal hypoglycemia. 195
• Do not continue increasing basal insulin beyond 0.5–1.0 U/kg/day without adding prandial coverage, as this leads to over‑basalization and higher hypoglycemia risk. 195

Insulin Management During Fasting in LADA

Basal Insulin Continuation

• Maintain basal insulin at a reduced dose (approximately 75 %–80 % of the usual total daily dose) throughout the fasting period to suppress hepatic glucose production even in the absence of food intake. This approach is supported by evidence from Diabetes Care (2024) and the British Journal of Anaesthesia (2016) and is considered a standard practice for patients with autoimmune diabetes. 197, 198

Prandial Insulin Holding

• Suspend all rapid‑acting (prandial) insulin doses during fasting hours because food‑stimulated glucose excursions are absent, and continuing prandial insulin increases the risk of hypoglycemia. This recommendation is based on the guideline presented in Diabetes Care (2024). 197

Prevention of Ketoacidosis

• Do not discontinue basal insulin entirely during fasting, as complete cessation can precipitate diabetic ketoacidosis in individuals with autoimmune diabetes. Continuous basal insulin, even at a reduced dose, provides essential suppression of lipolysis and ketogenesis. This safety measure is endorsed by both Diabetes Care (2024) and the British Journal of Anaesthesia (2016). 197, 198